BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943-1947. [PMID: 9072974 DOI: 10.1126/science.275.5308.1943] [Cited by in Crossref: 3265] [Cited by in F6Publishing: 3090] [Article Influence: 130.6] [Reference Citation Analysis]
Number Citing Articles
1 Wang X, Gjörloff-wingren A, Saxena M, Pathan N, Reed JC, Mustelin T. The Tumor Suppressor PTEN Regulates T Cell Survival and Antigen Receptor Signaling by Acting as a Phosphatidylinositol 3-Phosphatase. J Immunol 2000;164:1934-9. [DOI: 10.4049/jimmunol.164.4.1934] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 2.1] [Reference Citation Analysis]
2 Singh B, Ittmann MM, Krolewski JJ. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosom Cancer 1998;21:166-71. [DOI: 10.1002/(sici)1098-2264(199802)21:2<166::aid-gcc13>3.0.co;2-p] [Cited by in Crossref: 53] [Article Influence: 2.2] [Reference Citation Analysis]
3 Lancaster JM, Risinger JI, Carney ME, Barrett JC, Berchuck A. Mutational analysis of the PTEN gene in human uterine sarcomas. Am J Obstet Gynecol 2001;184:1051-3. [PMID: 11349153 DOI: 10.1067/mob.2001.114508] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
4 Kawanami T, Tanaka T, Hamaguchi Y, Nomiyama T, Nawata H, Yanase T. Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation. Endocrinology 2018;159:1774-92. [PMID: 29444261 DOI: 10.1210/en.2018-00099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wen X, Klionsky DJ. At a glance: A history of autophagy and cancer. Semin Cancer Biol 2020;66:3-11. [PMID: 31707087 DOI: 10.1016/j.semcancer.2019.11.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
6 Mi D, Yi J, Liu E, Li X. Relationsip between PTEN and VEGF expression and clinicopathological characteristics in HCC. J Huazhong Univ Sci Technolog Med Sci. 2006;26:682-685. [PMID: 17357488 DOI: 10.1007/s11596-006-0614-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
7 Konnikova L, Kotecki M, Kruger MM, Cochran BH. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer. 2003;3:23. [PMID: 13678425 DOI: 10.1186/1471-2407-3-23] [Cited by in Crossref: 166] [Cited by in F6Publishing: 164] [Article Influence: 8.7] [Reference Citation Analysis]
8 Barthel FP, Johnson KC, Wesseling P, Verhaak RGW. Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults. Neurol Clin 2018;36:421-37. [PMID: 30072063 DOI: 10.1016/j.ncl.2018.04.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
9 Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, McCubrey JA. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008;7:1745-62. [PMID: 18594202 DOI: 10.4161/cc.7.12.6166] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 4.7] [Reference Citation Analysis]
10 Vidal S, Bouzaher YH, El Motiam A, Seoane R, Rivas C. Overview of the regulation of the class IA PI3K/AKT pathway by SUMO. Semin Cell Dev Biol 2021:S1084-9521(21)00275-5. [PMID: 34753687 DOI: 10.1016/j.semcdb.2021.10.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Liu T, Song S, Wang X, Hao J. Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer. Eur J Med Chem 2021;210:112954. [PMID: 33158576 DOI: 10.1016/j.ejmech.2020.112954] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
12 Gillies Mckenna W, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 2003;22:5866-75. [DOI: 10.1038/sj.onc.1206699] [Cited by in Crossref: 101] [Cited by in F6Publishing: 79] [Article Influence: 5.3] [Reference Citation Analysis]
13 Grunt M, Zárský V, Cvrcková F. Roots of angiosperm formins: the evolutionary history of plant FH2 domain-containing proteins. BMC Evol Biol 2008;8:115. [PMID: 18430232 DOI: 10.1186/1471-2148-8-115] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 4.0] [Reference Citation Analysis]
14 Wu X, Rahal O, Kang J, Till SR, Prior RL, Simmen RC. In utero and lactational exposure to blueberry via maternal diet promotes mammary epithelial differentiation in prepubescent female rats. Nutr Res 2009;29:802-11. [PMID: 19932869 DOI: 10.1016/j.nutres.2009.10.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
15 Srividya MR, Thota B, Shailaja BC, Arivazhagan A, Thennarasu K, Chandramouli BA, Hegde AS, Santosh V. Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: a prospective translational study on a uniformly treated cohort of adult patients. Neuropathology 2011;31:376-83. [PMID: 21134002 DOI: 10.1111/j.1440-1789.2010.01178.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
16 Pappas G, Zumstein LA, Munshi A, Hobbs M, Meyn RE. Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene Ther 2007;14:543-9. [PMID: 17431403 DOI: 10.1038/sj.cgt.7701050] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
17 Nakada-Tsukui K, Watanabe N, Maehama T, Nozaki T. Phosphatidylinositol Kinases and Phosphatases in Entamoeba histolytica. Front Cell Infect Microbiol 2019;9:150. [PMID: 31245297 DOI: 10.3389/fcimb.2019.00150] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
18 Faucherre A, Taylor GS, Overvoorde J, Dixon JE, Hertog JD. Zebrafish pten genes have overlapping and non-redundant functions in tumorigenesis and embryonic development. Oncogene 2008;27:1079-86. [DOI: 10.1038/sj.onc.1210730] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 5.6] [Reference Citation Analysis]
19 Macoska JA, Xu J, Ziemnicka D, Schwab TS, Rubin MA, Kotula L. Loss of expression of human spectrin src homology domain binding protein 1 is associated with 10p loss in human prostatic adenocarcinoma. Neoplasia 2001;3:99-104. [PMID: 11420744 DOI: 10.1038/sj.neo.7900145] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
20 Bouali S, Chrétien A, Ramacci C, Rouyer M, Marchal S, Galenne T, Juin P, Becuwe P, Merlin J. P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. Cancer Gene Ther 2009;16:498-507. [DOI: 10.1038/cgt.2008.100] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
21 Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood 2008;111:4716-22. [PMID: 18299447 DOI: 10.1182/blood-2007-10-113068] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
22 Abdulkareem IH, Blair M. Phosphatase and tensin homologue deleted on chromosome 10. Niger Med J 2013;54:79-86. [PMID: 23798791 DOI: 10.4103/0300-1652.110033] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
23 den Hertog J. Tumor Suppressors in Zebrafish: From TP53 to PTEN and Beyond. Adv Exp Med Biol 2016;916:87-101. [PMID: 27165350 DOI: 10.1007/978-3-319-30654-4_4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
24 Gonzalez-Angulo AM, Blumenschein GR Jr. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 2013;39:313-20. [PMID: 23218708 DOI: 10.1016/j.ctrv.2012.11.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
25 Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 2011;17:1351-61. [PMID: 21138857 DOI: 10.1158/1078-0432.CCR-10-1905] [Cited by in Crossref: 62] [Cited by in F6Publishing: 37] [Article Influence: 5.2] [Reference Citation Analysis]
26 Zabell AP, Corden S, Helquist P, Stauffacher CV, Wiest O. Inhibition studies with rationally designed inhibitors of the human low molecular weight protein tyrosine phosphatase. Bioorg Med Chem 2004;12:1867-80. [PMID: 15051056 DOI: 10.1016/j.bmc.2004.01.042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
27 Jeng YM, Hsu HC. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer. 2003;105:625-629. [PMID: 12740910 DOI: 10.1002/ijc.11123] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 3.4] [Reference Citation Analysis]
28 Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S, Mori M. Reduced Expression of PTEN Protein and Its Prognostic Implications in Invasive Ductal Carcinoma of the Breast. Oncology 2005;68:398-404. [DOI: 10.1159/000086981] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 4.2] [Reference Citation Analysis]
29 Horn S, Endl E, Fehse B, Weck MM, Mayr GW, Jücker M. Restoration of SHIP activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/GSK-3beta signaling and leads to an increased transit time through the G1 phase of the cell cycle. Leukemia 2004;18:1839-49. [PMID: 15457186 DOI: 10.1038/sj.leu.2403529] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
30 Koul D, Yao Y, Abbruzzese JL, Yung WK, Reddy SA. Tumor suppressor MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway. J Biol Chem 2001;276:11402-8. [PMID: 11278366 DOI: 10.1074/jbc.M007806200] [Cited by in Crossref: 67] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
31 Xu W, Wang W. MicroRNA‑142‑5p modulates breast cancer cell proliferation and apoptosis by targeting phosphatase and tensin homolog. Mol Med Rep 2018;17:7529-36. [PMID: 29620260 DOI: 10.3892/mmr.2018.8812] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
32 Hägerstrand D, Lindh MB, Peña C, Garcia-Echeverria C, Nistér M, Hofmann F, Ostman A. PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. Neuro Oncol 2010;12:967-75. [PMID: 20378689 DOI: 10.1093/neuonc/noq029] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
33 Abdullah JM, Farizan A, Asmarina K, Zainuddin N, Ghazali MM, Jaafar H, Isa MN, Naing NN. Association of loss of heterozygosity and PTEN gene abnormalities with paraclinical, clinical modalities and survival time of glioma patients in Malaysia. Asian J Surg 2006;29:274-82. [PMID: 17098662 DOI: 10.1016/S1015-9584(09)60102-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
34 Qin W, Zheng Y, Qian BZ, Zhao M. Prostate Cancer Stem Cells and Nanotechnology: A Focus on Wnt Signaling. Front Pharmacol 2017;8:153. [PMID: 28400729 DOI: 10.3389/fphar.2017.00153] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
35 Cabral-Costa JV, Andreotti DZ, Mello NP, Scavone C, Camandola S, Kawamoto EM. Intermittent fasting uncovers and rescues cognitive phenotypes in PTEN neuronal haploinsufficient mice. Sci Rep 2018;8:8595. [PMID: 29872062 DOI: 10.1038/s41598-018-26814-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
36 Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 2011;57:1366-75. [PMID: 21956922 DOI: 10.1373/clinchem.2011.165977] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 7.5] [Reference Citation Analysis]
37 Chen YZ, Soeda E, Yang HW, Takita J, Chai L, Horii A, Inazawa J, Ohki M, Hayashi Y. Homozygous deletion in a neuroblastoma cell line defined by a high-density STS map spanning human chromosome band 1p36. Genes Chromosom Cancer 2001;31:326-32. [DOI: 10.1002/gcc.1151] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
38 Petrovics G, Li H, Stümpel T, Tan SH, Young D, Katta S, Li Q, Ying K, Klocke B, Ravindranath L, Kohaar I, Chen Y, Ribli D, Grote K, Zou H, Cheng J, Dalgard CL, Zhang S, Csabai I, Kagan J, Takeda D, Loda M, Srivastava S, Scherf M, Seifert M, Gaiser T, McLeod DG, Szallasi Z, Ebner R, Werner T, Sesterhenn IA, Freedman M, Dobi A, Srivastava S. A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. EBioMedicine 2015;2:1957-64. [PMID: 26844274 DOI: 10.1016/j.ebiom.2015.10.028] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
39 Whang YE, Wu X, Sawyers CL. Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene. J Natl Cancer Inst 1998;90:859-61. [PMID: 9625175 DOI: 10.1093/jnci/90.11.859] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
40 Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA, Nagle RB. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006;66:1203-12. [DOI: 10.1002/pros.20410] [Cited by in Crossref: 126] [Cited by in F6Publishing: 109] [Article Influence: 7.9] [Reference Citation Analysis]
41 Lachyankar MB, Sultana N, Schonhoff CM, Mitra P, Poluha W, Lambert S, Quesenberry PJ, Litofsky NS, Recht LD, Nabi R, Miller SJ, Ohta S, Neel BG, Ross AH. A role for nuclear PTEN in neuronal differentiation. J Neurosci 2000;20:1404-13. [PMID: 10662831 [PMID: 10662831 DOI: 10.1523/jneurosci.20-04-01404.2000] [Cited by in Crossref: 166] [Article Influence: 7.5] [Reference Citation Analysis]
42 Guha M, Plescia J, Leav I, Li J, Languino LR, Altieri DC. Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res 2009;69:4954-8. [PMID: 19470765 DOI: 10.1158/0008-5472.CAN-09-0584] [Cited by in Crossref: 43] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
43 Macken WL, Tischkowitz M, Lachlan KL. PTEN Hamartoma tumor syndrome in childhood: A review of the clinical literature. Am J Med Genet C Semin Med Genet 2019;181:591-610. [PMID: 31609537 DOI: 10.1002/ajmg.c.31743] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
44 Eng C. Cowden Syndrome. J Genet Counsel 1997;6:181-92. [DOI: 10.1023/a:1025664119494] [Cited by in Crossref: 81] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
45 Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, Huang SK, Colquhoun S, Hoon DS. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget. 2015;6:3211-3224. [PMID: 25633810 DOI: 10.18632/oncotarget.3085] [Cited by in Crossref: 101] [Cited by in F6Publishing: 100] [Article Influence: 16.8] [Reference Citation Analysis]
46 Sun W, Zhang DD, Guo L, Wang Q. Expression and significance of hypoxia-inducible factor-1α and its regulator phosphatase and tensin homolog deleted in chromosome 10 in gastric cancer. Shijie Huaren Xiaohua Zazhi 2007; 15(26): 2847-2851 [DOI: 10.11569/wcjd.v15.i26.2847] [Reference Citation Analysis]
47 Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 2002;33:405-9. [PMID: 12055674 DOI: 10.1053/hupa.2002.124721] [Cited by in Crossref: 103] [Cited by in F6Publishing: 90] [Article Influence: 5.2] [Reference Citation Analysis]
48 Skotland T, Ekroos K, Kauhanen D, Simolin H, Seierstad T, Berge V, Sandvig K, Llorente A. Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers. Eur J Cancer 2017;70:122-32. [PMID: 27914242 DOI: 10.1016/j.ejca.2016.10.011] [Cited by in Crossref: 135] [Cited by in F6Publishing: 139] [Article Influence: 22.5] [Reference Citation Analysis]
49 Yoo SB, Xu X, Lee HJ, Jheon S, Lee C, Choe G, Chung J. Loss of PTEN Expression is an Independent Poor Prognostic Factor in Non-small Cell Lung Cancer. Korean J Pathol 2011;45:329. [DOI: 10.4132/koreanjpathol.2011.45.4.329] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
50 Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Soda Y, Gage FH, Verma IM. Development of a novel mouse glioma model using lentiviral vectors. Nat Med. 2009;15:110-116. [PMID: 19122659 DOI: 10.1038/nm.1863] [Cited by in Crossref: 206] [Cited by in F6Publishing: 197] [Article Influence: 15.8] [Reference Citation Analysis]
51 Zhu Y, Wu Y, Shi W, Wang J, Yan X, Wang Q, Liu Y, Yang L, Gao L, Li M. Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial remodeling. Life Sci 2017;173:36-42. [PMID: 28212825 DOI: 10.1016/j.lfs.2017.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
52 Gupta S, Stuffrein S, Plattner R, Tencati M, Gray C, Whang YE, Stanbridge EJ. Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells. Mol Cell Biol 2001;21:5846-56. [PMID: 11486024 DOI: 10.1128/MCB.21.17.5846-5856.2001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
53 Paramio JM, Navarro M, Segrelles C, Gómez-casero E, Jorcano JL. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 1999;18:7462-8. [DOI: 10.1038/sj.onc.1203151] [Cited by in Crossref: 83] [Cited by in F6Publishing: 73] [Article Influence: 3.6] [Reference Citation Analysis]
54 Zhang Z, Zhou B, Xie L. Modulation of protein kinase signaling by protein phosphatases and inhibitors. Pharmacology & Therapeutics 2002;93:307-17. [DOI: 10.1016/s0163-7258(02)00199-7] [Cited by in Crossref: 64] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
55 Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A. 2000;97:1749-1753. [PMID: 10677529 DOI: 10.1073/pnas.040560897] [Cited by in Crossref: 376] [Cited by in F6Publishing: 358] [Article Influence: 17.1] [Reference Citation Analysis]
56 Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A 1998;95:13513-8. [PMID: 9811831 DOI: 10.1073/pnas.95.23.13513] [Cited by in Crossref: 818] [Cited by in F6Publishing: 785] [Article Influence: 34.1] [Reference Citation Analysis]
57 Henderson YC, Wang E, Clayman GL. Genotypic analysis of tumor suppressor genes PTEN/MMAC1 and p53 in head and neck squamous cell carcinomas. Laryngoscope 1998;108:1553-6. [PMID: 9778300 DOI: 10.1097/00005537-199810000-00024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
58 King JS, Teo R, Ryves J, Reddy JV, Peters O, Orabi B, Hoeller O, Williams RS, Harwood AJ. The mood stabiliser lithium suppresses PIP3 signalling in Dictyostelium and human cells. Dis Model Mech 2009;2:306-12. [PMID: 19383941 DOI: 10.1242/dmm.001271] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
59 Stephen RM, Pagel MD, Brown K, Baker AF, Meuillet EJ, Gillies RJ. Monitoring the development of xenograft triple-negative breast cancer models using diffusion-weighted magnetic resonance imaging. Exp Biol Med (Maywood) 2012;237:1273-80. [PMID: 23239438 DOI: 10.1258/ebm.2012.011326] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
60 Couto SS, Cao M, Duarte PC, Banach-Petrosky W, Wang S, Romanienko P, Wu H, Cardiff RD, Abate-Shen C, Cunha GR. Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. Differentiation 2009;77:103-11. [PMID: 19281769 DOI: 10.1016/j.diff.2008.09.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
61 Miyamoto S, Purcell NH, Smith JM, Gao T, Whittaker R, Huang K, Castillo R, Glembotski CC, Sussman MA, Newton AC, Brown JH. PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ Res 2010;107:476-84. [PMID: 20576936 DOI: 10.1161/CIRCRESAHA.109.215020] [Cited by in Crossref: 75] [Cited by in F6Publishing: 56] [Article Influence: 6.3] [Reference Citation Analysis]
62 Wang DY, Xiang YY, Li XJ, Hashimoto M, Tanaka M, Sugimura H. Mxi1 is a potential cellular target of carcinogens and frequently mutated in experimental rat tumors and tumor cell lines. Pathol Int 2000;50:373-83. [PMID: 10849326 DOI: 10.1046/j.1440-1827.2000.01057.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
63 Baba M, Schmidt LS, Linehan WM. Hereditary Renal Cell Carcinoma. In: Oya M, editor. Renal Cell Carcinoma. Tokyo: Springer Japan; 2017. pp. 19-82. [DOI: 10.1007/978-4-431-55531-5_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
64 Xia Q, Li W, Ali S, Xu M, Li Y, Li S, Meng X, Liu L, Dong L. Smurf1 silencing restores PTEN expression that ameliorates progression of human glioblastoma and sensitizes tumor cells to mTORC1/C2 inhibitor Torin1. iScience 2021;24:103528. [PMID: 34917902 DOI: 10.1016/j.isci.2021.103528] [Reference Citation Analysis]
65 Matsumoto CS, Almeida LO, Guimarães DM, Martins MD, Papagerakis P, Papagerakis S, Leopoldino AM, Castilho RM, Squarize CH. PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells. Oncotarget 2016;7:42393-407. [PMID: 27285754 DOI: 10.18632/oncotarget.9877] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
66 Cong M, Iwaisako K, Jiang C, Kisseleva T. Cell signals influencing hepatic fibrosis. Int J Hepatol. 2012;2012:158547. [PMID: 22973518 DOI: 10.1155/2012/158547] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
67 Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001;158:2097-106. [PMID: 11395387 DOI: 10.1016/S0002-9440(10)64681-0] [Cited by in Crossref: 177] [Cited by in F6Publishing: 58] [Article Influence: 8.4] [Reference Citation Analysis]
68 Moon SK, Kim HM, Kim CH. PTEN induces G1 cell cycle arrest and inhibits MMP-9 expression via the regulation of NF-kappaB and AP-1 in vascular smooth muscle cells. Arch Biochem Biophys. 2004;421:267-276. [PMID: 14984207 DOI: 10.1016/j.abb.2003.11.007] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 2.4] [Reference Citation Analysis]
69 Nieto-Sampedro M, Valle-Argos B, Gómez-Nicola D, Fernández-Mayoralas A, Nieto-Díaz M. Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol. 2011;5:265-314. [PMID: 22084619 DOI: 10.4137/cmo.s7685] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
70 Zysman MA, Chapman WB, Bapat B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol 2002;160:795-800. [PMID: 11891178 DOI: 10.1016/S0002-9440(10)64902-4] [Cited by in Crossref: 78] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
71 Maurice-duelli A, Ndoye A, Bouali S, Leroux A, Merlin J. Enhanced Cell Growth Inhibition following PTEN Nonviral Gene Transfer Using Polyethylenimine and Photochemical Internalization in Endometrial Cancer Cells. Technol Cancer Res Treat 2004;3:459-65. [DOI: 10.1177/153303460400300507] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
72 Van Calenbergh F, Vantomme N, Flamen P, Demaerel P, Sciot R, Legius E, Mortelmans L, Plets C. Lhermitte-Duclos disease: 11C-methionine positron emission tomography data in 4 patients. Surgical Neurology 2006;65:293-6. [DOI: 10.1016/j.surneu.2005.06.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
73 Wu P, Hu Y. Small molecules targeting phosphoinositide 3-kinases. Med Chem Commun 2012;3:1337. [DOI: 10.1039/c2md20044a] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
74 Delou JM, Biasoli D, Borges HL. The Complex Link between Apoptosis and Autophagy: a Promising New Role for RB. An Acad Bras Cienc. 2016;88:2257-2275. [PMID: 27991962 DOI: 10.1590/0001-3765201620160127] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
75 Yamamoto M, Metoki R, Yamamoto F. Systematic multiplex polymerase chain reaction and reverse transcription-polymerase chain reaction analyses of changes in copy number and expression of proto-oncogenes and tumor suppressor genes in cancer tissues and cell lines. Electrophoresis 2004;25:3349-56. [PMID: 15490458 DOI: 10.1002/elps.200406090] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
76 Pendaries C, Tronchère H, Plantavid M, Payrastre B. Phosphoinositide signaling disorders in human diseases. FEBS Letters 2003;546:25-31. [DOI: 10.1016/s0014-5793(03)00437-x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
77 Mitchell CJ, Kim MS, Zhong J, Nirujogi RS, Bose AK, Pandey A. Unbiased identification of substrates of protein tyrosine phosphatase ptp-3 in C. elegans. Mol Oncol 2016;10:910-20. [PMID: 27067626 DOI: 10.1016/j.molonc.2016.03.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
78 Yin D, Ogawa S, Kawamata N, Leiter A, Ham M, Li D, Doan NB, Said JW, Black KL, Phillip Koeffler H. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 2013;32:1155-63. [PMID: 22580610 DOI: 10.1038/onc.2012.132] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
79 Velarde MC, Demaria M, Campisi J. Senescent cells and their secretory phenotype as targets for cancer therapy. Interdiscip Top Gerontol 2013;38:17-27. [PMID: 23503512 DOI: 10.1159/000343572] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 8.0] [Reference Citation Analysis]
80 Qu Q, Shi Y. Neural stem cells in the developing and adult brains. J Cell Physiol 2009;221:5-9. [PMID: 19562676 DOI: 10.1002/jcp.21862] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
81 Pollack IF, Hamilton RL, Finkelstein SD, Lieberman F. Molecular abnormalities and correlations with tumor response and outcome in glioma patients. Neuroimaging Clinics of North America 2002;12:627-39. [DOI: 10.1016/s1052-5149(02)00030-8] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
82 Zhu L, Zhu Q, Wen H, Huang X, Zheng G. Mutations in GAS5 affect the transformation from benign prostate proliferation to aggressive prostate cancer by affecting the transcription efficiency of GAS5. J Cell Physiol 2019;234:8928-40. [PMID: 30317620 DOI: 10.1002/jcp.27561] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
83 Lodish MB, Stratakis CA. The differential diagnosis of familial lentiginosis syndromes. Fam Cancer 2011;10:481-90. [PMID: 21538076 DOI: 10.1007/s10689-011-9446-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
84 Zhou X, Yang X, Sun X, Xu X, Li X, Guo Y, Wang J, Li X, Yao L, Wang H, Shen L. Effect of PTEN loss on metabolic reprogramming in prostate cancer cells. Oncol Lett 2019;17:2856-66. [PMID: 30854061 DOI: 10.3892/ol.2019.9932] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
85 Mesti T, Ocvirk J. Malignant gliomas: old and new systemic treatment approaches. Radiol Oncol 2016;50:129-38. [PMID: 27247544 DOI: 10.1515/raon-2015-0003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
86 Lei K, Gu X, Alvarado AG, Du Y, Luo S, Ahn EH, Kang SS, Ji B, Liu X, Mao H, Fu H, Kornblum HI, Jin L, Li H, Ye K. Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma. J Hematol Oncol 2020;13:141. [PMID: 33087132 DOI: 10.1186/s13045-020-00979-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
87 Ponz de Leon M, Percesepe A. Pathogenesis of colorectal cancer. Dig Liver Dis. 2000;32:807-821. [PMID: 11215564 DOI: 10.1016/s1590-8658(00)80361-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
88 Xi Y, Qi Z, Ma J, Chen Y. PTEN loss activates a functional AKT/CXCR4 signaling axis to potentiate tumor growth and lung metastasis in human osteosarcoma cells. Clin Exp Metastasis 2020;37:173-85. [PMID: 31571016 DOI: 10.1007/s10585-019-09998-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
89 Dhar S, Kumar A, Rimando AM, Zhang X, Levenson AS. Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer. Oncotarget 2015;6:27214-26. [PMID: 26318586 DOI: 10.18632/oncotarget.4877] [Cited by in Crossref: 88] [Cited by in F6Publishing: 86] [Article Influence: 14.7] [Reference Citation Analysis]
90 Labbé DP, Hardy S, Tremblay ML. Protein tyrosine phosphatases in cancer: friends and foes! Prog Mol Biol Transl Sci. 2012;106:253-306. [PMID: 22340721 DOI: 10.1016/B978-0-12-396456-4.00009-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
91 Dart DA, Uysal-Onganer P, Jiang WG. Prostate-specific PTen deletion in mice activates inflammatory microRNA expression pathways in the epithelium early in hyperplasia development. Oncogenesis 2017;6:400. [PMID: 29284790 DOI: 10.1038/s41389-017-0007-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
92 Lee J, Li S, Torbenson M, Liu QZ, Lind S, Mulvihill JJ, Bane B, Wang J. Leiomyosarcoma of the breast: a pathologic and comparative genomic hybridization study of two cases. Cancer Genetics and Cytogenetics 2004;149:53-7. [DOI: 10.1016/s0165-4608(03)00286-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
93 Bellizzi AM, Bloomston M, Zhou X, Iwenofu OH, Frankel WL. The mTOR Pathway is Frequently Activated in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis. Applied Immunohistochemistry & Molecular Morphology 2010;18:442-7. [DOI: 10.1097/pai.0b013e3181de115b] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
94 Siraj MA, Jacobs AT, Tan GT. Altersolanol B, a fungal tetrahydroanthraquinone, inhibits the proliferation of estrogen receptor-expressing (ER+) human breast adenocarcinoma by modulating PI3K/AKT, p38/ERK MAPK and associated signaling pathways. Chemico-Biological Interactions 2022. [DOI: 10.1016/j.cbi.2022.109916] [Reference Citation Analysis]
95 Wang L, Wang WL, Zhang Y, Guo SP, Zhang J, Li QL. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res. 2007;37:389-396. [PMID: 17441812 DOI: 10.1111/j.1872-034x.2007.00042.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 45] [Article Influence: 7.5] [Reference Citation Analysis]
96 Strahl T, Thorner J. Synthesis and function of membrane phosphoinositides in budding yeast, Saccharomyces cerevisiae. Biochim Biophys Acta 2007;1771:353-404. [PMID: 17382260 DOI: 10.1016/j.bbalip.2007.01.015] [Cited by in Crossref: 204] [Cited by in F6Publishing: 198] [Article Influence: 13.6] [Reference Citation Analysis]
97 Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V, Minna JD, Gazdar AF. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 1998;21:308-19. [PMID: 9559342 DOI: 10.1002/(sici)1098-2264(199804)21:4<308::aid-gcc4>3.0.co;2-2] [Cited by in Crossref: 119] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
98 Noguera NI, Song MS, Divona M, Catalano G, Calvo KL, García F, Ottone T, Florenzano F, Faraoni I, Battistini L, Colombo E, Amadori S, Pandolfi PP, Lo-Coco F. Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia. Leukemia 2013;27:1037-43. [PMID: 23183427 DOI: 10.1038/leu.2012.314] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
99 Gimm O, Chi H, Dahia PL, Perren A, Hinze R, Komminoth P, Dralle H, Reynolds PR, Eng C. Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas. J Clin Endocrinol Metab 2001;86:1801-5. [PMID: 11297621 DOI: 10.1210/jcem.86.4.7419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
100 Tang X, Powelka AM, Soriano NA, Czech MP, Guilherme A. PTEN, but Not SHIP2, Suppresses Insulin Signaling through the Phosphatidylinositol 3-Kinase/Akt Pathway in 3T3-L1 Adipocytes. Journal of Biological Chemistry 2005;280:22523-9. [DOI: 10.1074/jbc.m501949200] [Cited by in Crossref: 82] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
101 Liang T, Gao F, Chen J. Role of PTEN-less in cardiac injury, hypertrophy and regeneration. Cell Regen 2021;10:25. [PMID: 34337686 DOI: 10.1186/s13619-021-00087-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Meng Y, Cai KQ, Moore R, Tao W, Tse JD, Smith ER, Xu XX. Pten facilitates epiblast epithelial polarization and proamniotic lumen formation in early mouse embryos. Dev Dyn 2017;246:517-30. [PMID: 28387983 DOI: 10.1002/dvdy.24503] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
103 Young BP, Post KL, Chao JT, Meili F, Haas K, Loewen C. Sentinel interaction mapping - a generic approach for the functional analysis of human disease gene variants using yeast. Dis Model Mech 2020;13:dmm044560. [PMID: 32471850 DOI: 10.1242/dmm.044560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Xiong Q, Oviedo HV, Trotman LC, Zador AM. PTEN regulation of local and long-range connections in mouse auditory cortex. J Neurosci 2012;32:1643-52. [PMID: 22302806 DOI: 10.1523/JNEUROSCI.4480-11.2012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
105 Aitchison A, Warren A, Neal D, Rabbitts P. RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate 2007;67:638-44. [DOI: 10.1002/pros.20475] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
106 Martín MG. The Biology of Inherited Disorders of the Gastrointestinal Tract Part I: Gastrointestinal Disorders: . Journal of Pediatric Gastroenterology & Nutrition 1998;26:321-35. [DOI: 10.1097/00005176-199803000-00016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
107 Chen L, Guo D. The functions of tumor suppressor PTEN in innate and adaptive immunity. Cell Mol Immunol 2017;14:581-9. [PMID: 28603282 DOI: 10.1038/cmi.2017.30] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
108 Church JE, Qian J, Kumar S, Black SM, Venema RC, Papapetropoulos A, Fulton DJ. Inhibition of endothelial nitric oxide synthase by the lipid phosphatase PTEN. Vascul Pharmacol 2010;52:191-8. [PMID: 19962452 DOI: 10.1016/j.vph.2009.11.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
109 Kyrgidis A, Tzellos TG, Triaridis S. Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. J Carcinog 2010;9:3. [PMID: 20442802 DOI: 10.4103/1477-3163.62141] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
110 Li B, Smith TJ. PI3K/AKT pathway mediates induction of IL-1RA by TSH in fibrocytes: modulation by PTEN. J Clin Endocrinol Metab 2014;99:3363-72. [PMID: 24840811 DOI: 10.1210/jc.2014-1257] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
111 Omori N, Jin G, Li F, Zhang W, Wang S, Hamakawa Y, Nagano I, Manabe Y, Shoji M, Abe K. Enhanced phosphorylation of PTEN in rat brain after transient middle cerebral artery occlusion. Brain Research 2002;954:317-22. [DOI: 10.1016/s0006-8993(02)03366-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
112 Azimi I, Milevskiy MJG, Kaemmerer E, Turner D, Yapa KTDS, Brown MA, Thompson EW, Roberts-Thomson SJ, Monteith GR. TRPC1 is a differential regulator of hypoxia-mediated events and Akt signalling in PTEN-deficient breast cancer cells. J Cell Sci 2017;130:2292-305. [PMID: 28559303 DOI: 10.1242/jcs.196659] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 10.4] [Reference Citation Analysis]
113 Park NI, Rogan PK, Tarnowski HE, Knoll JH. Structural and genic characterization of stable genomic regions in breast cancer: relevance to chemotherapy. Mol Oncol 2012;6:347-59. [PMID: 22342187 DOI: 10.1016/j.molonc.2012.01.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
114 Rasool S, Rasool V, Naqvi T, Ganai BA, Shah BA. Genetic unraveling of colorectal cancer. Tumour Biol. 2014;35:5067-5082. [PMID: 24573608 DOI: 10.1007/s13277-014-1713-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
115 Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol. 2009;36 Suppl 3:S3-S17. [PMID: 19963098 DOI: 10.1053/j.seminoncol.2009.10.011] [Cited by in Crossref: 147] [Cited by in F6Publishing: 140] [Article Influence: 12.3] [Reference Citation Analysis]
116 Couto SS, Bolon B, Cardiff RD. Morphologic manifestations of gene-specific molecular alterations ("genetic addictions") in mouse models of disease. Vet Pathol 2012;49:116-29. [PMID: 22173978 DOI: 10.1177/0300985811430962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
117 Volders PJ, Lefever S, Baute S, Nuytens J, Vanderheyden K, Menten B, Mestdagh P, Vandesompele J. Targeted Genomic Screen Reveals Focal Long Non-Coding RNA Copy Number Alterations in Cancer Cell Lines. Noncoding RNA 2018;4:E21. [PMID: 30217017 DOI: 10.3390/ncrna4030021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
118 Pascual J, Turner N. Targeting the PI3-kinase pathway in triple-negative breast cancer. Annals of Oncology 2019;30:1051-60. [DOI: 10.1093/annonc/mdz133] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 17.7] [Reference Citation Analysis]
119 Liu Z, Ke F, Duan C, Lan H, Li J, Gao C, Li J, Zhong Z. Mannan-conjugated adenovirus enhanced gene therapy effects on murine hepatocellular carcinoma cells in vitro and in vivo. Bioconjug Chem 2013;24:1387-97. [PMID: 23937094 DOI: 10.1021/bc400215a] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
120 Liu J, Chin-Sang ID. C. elegans as a model to study PTEN's regulation and function. Methods 2015;77-78:180-90. [PMID: 25514044 DOI: 10.1016/j.ymeth.2014.12.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
121 Kumar R, Srinivasan S, Koduru S, Pahari P, Rohr J, Kyprianou N, Damodaran C. Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells. Cancer Prev Res (Phila) 2009;2:234-43. [PMID: 19223576 DOI: 10.1158/1940-6207.CAPR-08-0129] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
122 Kosmas K, Mitropoulou G, Provatas I, Stamoulas M, Marouga A. Expression of phosphatase and tensin homologue in imprint smears of endometrial carcinoma. Cytopathology 2018;29:558-64. [PMID: 30007089 DOI: 10.1111/cyt.12612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
123 Brandmaier A, Hou SQ, Demaria S, Formenti SC, Shen WH. PTEN at the interface of immune tolerance and tumor suppression. Front Biol (Beijing) 2017;12:163-74. [PMID: 29527223 DOI: 10.1007/s11515-017-1443-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
124 Nishiyama H, Takahashi T, Kakehi Y, Habuchi T, Knowles MA. Homozygous deletion at the 9q32-33 candidate tumor suppressor locus in primary human bladder cancer. Genes Chromosom Cancer 1999;26:171-5. [DOI: 10.1002/(sici)1098-2264(199910)26:2<171::aid-gcc10>3.0.co;2-b] [Cited by in Crossref: 24] [Article Influence: 1.0] [Reference Citation Analysis]
125 Carracedo A, Alimonti A, Pandolfi PP. PTEN level in tumor suppression: how much is too little? Cancer Res 2011;71:629-33. [PMID: 21266353 DOI: 10.1158/0008-5472.CAN-10-2488] [Cited by in Crossref: 172] [Cited by in F6Publishing: 94] [Article Influence: 15.6] [Reference Citation Analysis]
126 Koenig A, Bianco SR, Fosmire S, Wojcieszyn J, Modiano JF. Expression and Significance of p53, Rb, p21/waf-1, p16/ink-4a, and PTEN Tumor Suppressors in Canine Melanoma. Vet Pathol 2002;39:458-72. [DOI: 10.1354/vp.39-4-458] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 12.5] [Reference Citation Analysis]
127 Kaur P, Shukla S, Gupta S. Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study. Carcinogenesis. 2008;29:2210-2217. [PMID: 18725386 DOI: 10.1093/carcin/bgn201] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
128 Revandkar A, Perciato ML, Toso A, Alajati A, Chen J, Gerber H, Dimitrov M, Rinaldi A, Delaleu N, Pasquini E, D'Antuono R, Pinton S, Losa M, Gnetti L, Arribas A, Fraering P, Bertoni F, Nepveu A, Alimonti A. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence. Nat Commun 2016;7:13719. [PMID: 27941799 DOI: 10.1038/ncomms13719] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
129 Machida H, Nakajima S, Shikano N, Nishio J, Okada S, Asayama M, Shirai M, Kubota N. Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis. Cancer Sci 2005;96:911-7. [PMID: 16367912 DOI: 10.1111/j.1349-7006.2005.00125.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
130 Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet. 1997;16:333-334. [PMID: 9241266 DOI: 10.1038/ng0897-333] [Cited by in Crossref: 423] [Cited by in F6Publishing: 389] [Article Influence: 16.9] [Reference Citation Analysis]
131 Miyakawa A, Ichimura K, Schmidt EE, Varmeh-Ziaie S, Collins VP. Multiple deleted regions on the long arm of chromosome 6 in astrocytic tumours. Br J Cancer 2000;82:543-9. [PMID: 10682663 DOI: 10.1054/bjoc.1999.0961] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.1] [Reference Citation Analysis]
132 Xie P, Cao H, Li Y, Wang J, Cui Z. Knockdown of lncRNA CCAT2 inhibits endometrial cancer cells growth and metastasis via sponging miR-216b. Cancer Biomark 2017;21:123-33. [PMID: 29036788 DOI: 10.3233/CBM-170388] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
133 Wang H, Zhang P, Lin C, Yu Q, Wu J, Wang L, Cui Y, Wang K, Gao Z, Li H. Relevance and therapeutic possibility of PTEN-long in renal cell carcinoma. PLoS One 2015;10:e114250. [PMID: 25714556 DOI: 10.1371/journal.pone.0114250] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
134 Ren W, Duan Y, Yang Y, Ji Y, Chen F. Down-regulation of Stat3 induces apoptosis of human glioma cell: a potential method to treat brain cancer. Neurol Res 2008;30:297-301. [PMID: 17716392 DOI: 10.1179/016164107X230784] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
135 Levy JJ, Chen Y, Azizgolshani N, Petersen CL, Titus AJ, Moen EL, Vaickus LJ, Salas LA, Christensen BC. MethylSPWNet and MethylCapsNet: Biologically Motivated Organization of DNAm Neural Networks, Inspired by Capsule Networks. NPJ Syst Biol Appl 2021;7:33. [PMID: 34417465 DOI: 10.1038/s41540-021-00193-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Robinson S, Cohen AR. Cowden Disease and Lhermitte-Duclos Disease: Characterization of a New Phakomatosis. Neurosurgery 2000;46:371-371. [DOI: 10.1097/00006123-200002000-00021] [Cited by in Crossref: 67] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
137 Nakdimon I, Walser M, Fröhli E, Hajnal A. PTEN negatively regulates MAPK signaling during Caenorhabditis elegans vulval development. PLoS Genet 2012;8:e1002881. [PMID: 22916028 DOI: 10.1371/journal.pgen.1002881] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
138 Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, D'Hondt L, Strauven T, Chaskis C, In't Veld P, Michotte A, De Greve J. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 2009;20:1596-603. [PMID: 19491283 DOI: 10.1093/annonc/mdp032] [Cited by in Crossref: 151] [Cited by in F6Publishing: 134] [Article Influence: 11.6] [Reference Citation Analysis]
139 Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, Zauderer MG, Lolkema MP, Apt D, Yeh RF, Fredrickson JO, Spoerke JM, Koeppen H, Ware JA, Lauchle JO, Burris HA 3rd, de Bono JS. Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res 2016;22:2874-84. [PMID: 26787751 DOI: 10.1158/1078-0432.CCR-15-2225] [Cited by in Crossref: 65] [Cited by in F6Publishing: 35] [Article Influence: 10.8] [Reference Citation Analysis]
140 Li QJ, Cai JQ, Liu CY. Evolving Molecular Genetics of Glioblastoma. Chin Med J (Engl) 2016;129:464-71. [PMID: 26879021 DOI: 10.4103/0366-6999.176065] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
141 Prochownik EV, Grove LE, Deubler D, Zhu XL, Stephenson RA, Rohr LR, Yin X, Brothman AR. Commonly occurring loss and mutation of theMXI1 gene in prostate cancer. Genes Chromosom Cancer 1998;22:295-304. [DOI: 10.1002/(sici)1098-2264(199808)22:4<295::aid-gcc5>3.0.co;2-q] [Cited by in Crossref: 44] [Article Influence: 1.8] [Reference Citation Analysis]
142 Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem 2003;278:42992-3000. [PMID: 12933816 DOI: 10.1074/jbc.M306295200] [Cited by in Crossref: 124] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
143 Yuan L, Lv Y, Li H, Gao H, Song S, Zhang Y, Xing G, Kong X, Wang L, Li Y, Zhou T, Gao D, Xiao ZX, Yin Y, Wei W, He F, Zhang L. Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis. Nat Cell Biol 2015;17:1169-81. [PMID: 26280536 DOI: 10.1038/ncb3218] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 9.3] [Reference Citation Analysis]
144 Fu S, Deng Q, Yang W, Ding H, Wang X, Li P, Li X, Wang Z, Li X, Liu G. Increase of Fatty Acid Oxidation and VLDL Assembly and Secretion Overexpression of PTEN in Cultured Hepatocytes of Newborn Calf. Cell Physiol Biochem 2012;30:1005-13. [DOI: 10.1159/000341477] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
145 Pinson JA, Zheng Z, Miller MS, Chalmers DK, Jennings IG, Thompson PE. L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ. ACS Med Chem Lett 2013;4:206-10. [PMID: 23795239 DOI: 10.1021/ml300336j] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
146 Wu KL, Wu CA, Wu CW, Chan SH, Chang AY, Chan JY. Redox-sensitive oxidation and phosphorylation of PTEN contribute to enhanced activation of PI3K/Akt signaling in rostral ventrolateral medulla and neurogenic hypertension in spontaneously hypertensive rats. Antioxid Redox Signal 2013;18:36-50. [PMID: 22746319 DOI: 10.1089/ars.2011.4457] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
147 Broadbent D, Ahmadzai MM, Kammala AK, Yang C, Occhiuto C, Das R, Subramanian H. Roles of NHERF Family of PDZ-Binding Proteins in Regulating GPCR Functions. Adv Immunol. 2017;136:353-385. [PMID: 28950951 DOI: 10.1016/bs.ai.2017.05.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
148 Moniz LS, Surinova S, Ghazaly E, Velasco LG, Haider S, Rodríguez-Prados JC, Berenjeno IM, Chelala C, Vanhaesebroeck B. Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate. Sci Rep 2017;7:39985. [PMID: 28059163 DOI: 10.1038/srep39985] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
149 Cuffe S, Dowling CM, Claffey J, Pampillón C, Hogan M, Fitzpatrick JM, Carty MP, Tacke M, Watson RW. Effects of titanocene dichloride derivatives on prostate cancer cells, specifically DNA damage-induced apoptosis. Prostate 2011;71:111-24. [PMID: 20665530 DOI: 10.1002/pros.21227] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
150 Zhao Z, Xu Q, Wei R, Huang L, Wang W, Wei G, Ni T. Comprehensive characterization of somatic variants associated with intronic polyadenylation in human cancers. Nucleic Acids Res 2021;49:10369-81. [PMID: 34508351 DOI: 10.1093/nar/gkab772] [Reference Citation Analysis]
151 Fujisawa H, Kurrer M, Reis RM, Yonekawa Y, Kleihues P, Ohgaki H. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am J Pathol 1999;155:387-94. [PMID: 10433932 DOI: 10.1016/S0002-9440(10)65135-8] [Cited by in Crossref: 80] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
152 Schmitt-Ney M. The FOXO's Advantages of Being a Family: Considerations on Function and Evolution. Cells 2020;9:E787. [PMID: 32214027 DOI: 10.3390/cells9030787] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
153 Rübel A, Handrick R, Lindner LH, Steiger M, Eibl H, Budach W, Belka C, Jendrossek V. The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro. Radiat Oncol. 2006;1:6. [PMID: 16722524 DOI: 10.1186/1748-717x-1-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
154 Diaz-Meco MT, Abu-Baker S. The Par-4/PTEN connection in tumor suppression. Cell Cycle 2009;8:2518-22. [PMID: 19625770 DOI: 10.4161/cc.8.16.9384] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
155 Zhang Y, Dong Y, Melkus MW, Yin S, Tang SN, Jiang P, Pramanik K, Wu W, Kim S, Ye M, Hu H, Lu J, Jiang C. Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin. Mol Cancer Ther 2018;17:2341-52. [PMID: 30166403 DOI: 10.1158/1535-7163.MCT-17-1296] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
156 Murakami Y, Sekiya T. Accumulation of genetic alterations and their significance in each primary human cancer and cell line. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1998;400:421-37. [DOI: 10.1016/s0027-5107(98)00031-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
157 Zhao C, Thompson BJ, Chen K, Gao F, Blouw B, Marella M, Zimmerman S, Kimbler T, Garrovillo S, Bahn J, Huang L, Huang Z, Shepard HM, Rosengren S, Thanos CD, Maneval DC. The growth of a xenograft breast cancer tumor model with engineered hyaluronan-accumulating stroma is dependent on hyaluronan and independent of CD44. Oncotarget 2019;10:6561-76. [PMID: 31762938 DOI: 10.18632/oncotarget.27302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Lee K, Nam KT, Cho SH, Gudapati P, Hwang Y, Park DS, Potter R, Chen J, Volanakis E, Boothby M. Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia. J Exp Med 2012;209:713-28. [PMID: 22473959 DOI: 10.1084/jem.20111470] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 8.6] [Reference Citation Analysis]
159 Li L, Ernsting BR, Wishart MJ, Lohse DL, Dixon JE. A Family of Putative Tumor Suppressors Is Structurally and Functionally Conserved in Humans and Yeast. Journal of Biological Chemistry 1997;272:29403-6. [DOI: 10.1074/jbc.272.47.29403] [Cited by in Crossref: 110] [Cited by in F6Publishing: 103] [Article Influence: 4.4] [Reference Citation Analysis]
160 Mavros A, Hahn M, Wieland I, Koy S, Koufaki ON, Strelocke K, Koch R, Haroske G, Schackert HK, Eckelt U. Infrequent genetic alterations of the tumor suppressor gene PTEN/MMAC1 in squamous cell carcinoma of the oral cavity: Genetic alterations of PTEN/MMAC1 in oral cancer. Journal of Oral Pathology & Medicine 2002;31:270-6. [DOI: 10.1034/j.1600-0714.2002.310504.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
161 Martin SA, Ouchi T. Cellular commitment to reentry into the cell cycle after stalled DNA is determined by site-specific phosphorylation of Chk1 and PTEN. Mol Cancer Ther 2008;7:2509-16. [PMID: 18723495 DOI: 10.1158/1535-7163.MCT-08-0199] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
162 Noch E, Khalili K. Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol Ther 2009;8:1791-7. [PMID: 19770591 DOI: 10.4161/cbt.8.19.9762] [Cited by in Crossref: 80] [Cited by in F6Publishing: 78] [Article Influence: 6.7] [Reference Citation Analysis]
163 Phuphanich S, Brat DJ, Olson JJ. Delivery systems and molecular targets of mechanism-based therapies for GBM. Expert Rev Neurother 2004;4:649-63. [PMID: 15853584 DOI: 10.1586/14737175.4.4.649] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
164 Carrasco DR, Fenton T, Sukhdeo K, Protopopova M, Enos M, You MJ, Divicio D, Nogueira C, Stommel J, Pinkus GS, Fletcher C, Hornick JL, Cavenee WK, Furnari FB, Depinho RA. The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell 2006;9:379-90. [DOI: 10.1016/j.ccr.2006.03.028] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
165 White MK, Khalili K. CRISPR/Cas9 and cancer targets: future possibilities and present challenges. Oncotarget 2016;7:12305-17. [PMID: 26840090 DOI: 10.18632/oncotarget.7104] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10:631. [PMID: 21087480 DOI: 10.1186/1471-2407-10-631] [Cited by in Crossref: 110] [Cited by in F6Publishing: 105] [Article Influence: 9.2] [Reference Citation Analysis]
167 Qi Q, Ling Y, Zhu M, Zhou L, Wan M, Bao Y, Liu Y. Promoter region methylation and loss of protein expression of PTEN and significance in cervical cancer. Biomed Rep 2014;2:653-8. [PMID: 25054006 DOI: 10.3892/br.2014.298] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
168 Zhu Y, Hoell P, Ahlemeyer B, Sure U, Bertalanffy H, Krieglstein J. Implication of PTEN in production of reactive oxygen species and neuronal death in in vitro models of stroke and Parkinson's disease. Neurochem Int 2007;50:507-16. [PMID: 17169462 DOI: 10.1016/j.neuint.2006.10.010] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
169 Belletti B, Prisco M, Morrione A, Valentinis B, Navarro M, Baserga R. Regulation of Id2 gene expression by the insulin-like growth factor I receptor requires signaling by phosphatidylinositol 3-kinase. J Biol Chem 2001;276:13867-74. [PMID: 11278691 DOI: 10.1074/jbc.M010509200] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
170 Tsuda H, Takarabe T, Okada S, Uchida H, Kasamatsu T, Yamada T, Tsunematsu R, Ohmi K, Hirohashi S. Different pattern of loss of heterozygosity among endocervical-type adenocarcinoma, endometrioid-type adenocarcinoma and adenoma malignum of the uterine cervix. Int J Cancer 2002;98:713-7. [DOI: 10.1002/ijc.10228] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
171 Zhang J, Jia J, Zhu F, Ma X, Han B, Wei X, Tan C, Jiang Y, Chen Y. Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors. Mol Biosyst 2012;8:2645-56. [PMID: 22833077 DOI: 10.1039/c2mb25165e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
172 Li G, Hu Y, Huo Y, Liu M, Freeman D, Gao J, Liu X, Wu DC, Wu H. PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin. J Biol Chem 2006;281:10663-8. [PMID: 16507572 DOI: 10.1074/jbc.M512509200] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
173 Hosoya Y, Gemma A, Seike M, Kurimoto F, Uematsu K, Hibino S, Yoshimura A, Shibuya M, Kudoh S. Alteration of the PTEN/MMAC1 gene locus in primary lung cancer with distant metastasis. Lung Cancer. 1999;25:87-93. [PMID: 10470842 DOI: 10.1016/s0169-5002(99)00052-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
174 Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34-45. [PMID: 11900250 DOI: 10.1038/35094009] [Cited by in Crossref: 1610] [Cited by in F6Publishing: 1472] [Article Influence: 80.5] [Reference Citation Analysis]
175 Hu Y, An Y, Fang N, Li Y, Jin H, Nazarali A, Ji S. The Optimization of Soluble PTEN Expression in Escherichia coli. Open Biochem J 2015;9:42-8. [PMID: 26464590 DOI: 10.2174/1874091X01509010042] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
176 Meng Q, Goldberg ID, Rosen EM, Fan S. Inhibitory effects of Indole-3-carbinol on invasion and migration in human breast cancer cells. Breast Cancer Res Treat. 2000;63:147-152. [PMID: 11097090 DOI: 10.1023/a:1006495824158] [Cited by in Crossref: 65] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
177 Chen Z, Thomas SN, Bolduc DM, Jiang X, Zhang X, Wolberger C, Cole PA. Enzymatic Analysis of PTEN Ubiquitylation by WWP2 and NEDD4-1 E3 Ligases. Biochemistry 2016;55:3658-66. [PMID: 27295432 DOI: 10.1021/acs.biochem.6b00448] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
178 Maxwell KN, Domchek SM. Familial Breast Cancer Risk. Curr Breast Cancer Rep 2013;5:170-82. [DOI: 10.1007/s12609-013-0117-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
179 Eason RR, Velarde MC, Chatman L Jr, Till SR, Geng Y, Ferguson M, Badger TM, Simmen RC. Dietary exposure to whey proteins alters rat mammary gland proliferation, apoptosis, and gene expression during postnatal development. J Nutr 2004;134:3370-7. [PMID: 15570039 DOI: 10.1093/jn/134.12.3370] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
180 Georgescu MM, Li Y, Islam MZ, Notarianni C, Sun H, Olar A, Fuller GN. Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications. Oncotarget 2019;10:4038-52. [PMID: 31258848 DOI: 10.18632/oncotarget.27005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
181 Chou TT, Trojanowski JQ, Lee VM. Neurotrophin signal transduction in medulloblastoma. J Neurosci Res 1997;49:522-7. [DOI: 10.1002/(sici)1097-4547(19970901)49:5<522::aid-jnr2>3.0.co;2-d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
182 Chen W, Robertson AJ, Ganesamoorthy D, Coin LJM. sCNAphase: using haplotype resolved read depth to genotype somatic copy number alterations from low cellularity aneuploid tumors. Nucleic Acids Res 2017;45:e34. [PMID: 27903916 DOI: 10.1093/nar/gkw1086] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
183 Chen X, Liu B, Li Q, Honorio S, Liu X, Liu C, Multani AS, Calhoun-Davis T, Tang DG. Dissociated primary human prostate cancer cells coinjected with the immortalized Hs5 bone marrow stromal cells generate undifferentiated tumors in NOD/SCID-γ mice. PLoS One 2013;8:e56903. [PMID: 23451107 DOI: 10.1371/journal.pone.0056903] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
184 Wang R, Lu YJ, Fisher C, Bridge JA, Shipley J. Characterization of chromosome aberrations associated with soft-tissue leiomyosarcomas by twenty-four-color karyotyping and comparative genomic hybridization analysis. Genes Chromosomes Cancer 2001;31:54-64. [PMID: 11284036 DOI: 10.1002/gcc.1118] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 2.0] [Reference Citation Analysis]
185 Yehia L, Ngeow J, Eng C. PTEN-opathies: from biological insights to evidence-based precision medicine. J Clin Invest 2019;129:452-64. [PMID: 30614812 DOI: 10.1172/JCI121277] [Cited by in Crossref: 64] [Cited by in F6Publishing: 37] [Article Influence: 21.3] [Reference Citation Analysis]
186 Braud A, de Rocquancourt A, Marty M, Espie M. Cowden disease and Lhermitte Duclos disease, markers of breast carcinoma: Report of two patients. Annals of Oncology 1999;10:1241-3. [DOI: 10.1023/a:1008317923860] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
187 Ghosh AK, Grigorieva I, Steele R, Hoover RG, Ray RB. PTEN transcriptionally modulates c-myc gene expression in human breast carcinoma cells and is involved in cell growth regulation. Gene. 1999;235:85-91. [PMID: 10415336 DOI: 10.1016/s0378-1119(99)00206-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
188 Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, Dedhar S. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci U S A. 2000;97:3207-3212. [PMID: 10716737 DOI: 10.1073/pnas.060579697] [Cited by in Crossref: 64] [Cited by in F6Publishing: 137] [Article Influence: 2.9] [Reference Citation Analysis]
189 Nakae J, Kido Y, Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev. 2001;22:818-835. [PMID: 11739335 DOI: 10.1210/edrv.22.6.0452] [Cited by in Crossref: 267] [Cited by in F6Publishing: 293] [Article Influence: 13.4] [Reference Citation Analysis]
190 Aganezov S, Goodwin S, Sherman RM, Sedlazeck FJ, Arun G, Bhatia S, Lee I, Kirsche M, Wappel R, Kramer M, Kostroff K, Spector DL, Timp W, McCombie WR, Schatz MC. Comprehensive analysis of structural variants in breast cancer genomes using single-molecule sequencing. Genome Res 2020;30:1258-73. [PMID: 32887686 DOI: 10.1101/gr.260497.119] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
191 Stiles B, Groszer M, Wang S, Jiao J, Wu H. PTENless means more. Dev Biol 2004;273:175-84. [PMID: 15328005 DOI: 10.1016/j.ydbio.2004.06.008] [Cited by in Crossref: 167] [Cited by in F6Publishing: 167] [Article Influence: 9.3] [Reference Citation Analysis]
192 Patel M, Gomez NC, McFadden AW, Moats-Staats BM, Wu S, Rojas A, Sapp T, Simon JM, Smith SV, Kaiser-Rogers K, Davis IJ. PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition. Mol Cancer Res 2014;12:1610-20. [PMID: 24994750 DOI: 10.1158/1541-7786.MCR-14-0006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
193 Al Bashir S, Alzoubi A, Alfaqih MA, Kheirallah K, Smairat A, Haddad H, Al-Dwairy A, Fawwaz BAB, Alzoubi M, Trpkov K. PTEN Loss in a Prostate Cancer Cohort From Jordan. Appl Immunohistochem Mol Morphol 2020;28:389-94. [PMID: 30614821 DOI: 10.1097/PAI.0000000000000732] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
194 Carnero A, Paramio JM. The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Front Oncol 2014;4:252. [PMID: 25295225 DOI: 10.3389/fonc.2014.00252] [Cited by in Crossref: 95] [Cited by in F6Publishing: 102] [Article Influence: 11.9] [Reference Citation Analysis]
195 Choi Y, Zhang J, Murga C, Yu H, Koller E, Monia BP, Gutkind JS, Li W. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene. 2002;21:5289-5300. [PMID: 12149650 DOI: 10.1038/sj.onc.1205650] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 3.5] [Reference Citation Analysis]
196 Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24:7465-74. [PMID: 16288293 DOI: 10.1038/sj.onc.1209096] [Cited by in Crossref: 241] [Cited by in F6Publishing: 224] [Article Influence: 14.2] [Reference Citation Analysis]
197 Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 2009;21:199-208. [PMID: 19200708 DOI: 10.1016/j.ceb.2008.12.007] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.9] [Reference Citation Analysis]
198 Bansal K, Liang ML, Rutka JT. Molecular biology of human gliomas. Technol Cancer Res Treat 2006;5:185-94. [PMID: 16700615 DOI: 10.1177/153303460600500302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
199 Zhang X, Jin T, Huang X, Liu X, Liu Z, Jia Y, Hao J. Effects of the tumor suppressor PTEN on biological behaviors of activated pancreatic stellate cells in pancreatic fibrosis. Exp Cell Res 2018;373:132-44. [PMID: 30321515 DOI: 10.1016/j.yexcr.2018.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
200 De Vivo I, Cui X, Domen J, Cleary ML. Growth stimulation of primary B cell precursors by the anti-phosphatase Sbf1. Proc Natl Acad Sci U S A 1998;95:9471-6. [PMID: 9689104 DOI: 10.1073/pnas.95.16.9471] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
201 Mehenni H, Gehrig C, Nezu J, Oku A, Shimane M, Rossier C, Guex N, Blouin JL, Scott HS, Antonarakis SE. Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet 1998;63:1641-50. [PMID: 9837816 DOI: 10.1086/302159] [Cited by in Crossref: 135] [Cited by in F6Publishing: 117] [Article Influence: 5.6] [Reference Citation Analysis]
202 Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. PTEN Gene Alterations in Lymphoid Neoplasms. Blood 1998;92:3410-5. [DOI: 10.1182/blood.v92.9.3410.421a06_3410_3415] [Cited by in Crossref: 8] [Article Influence: 0.3] [Reference Citation Analysis]
203 Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci U S A 2009;106:480-5. [PMID: 19114656 DOI: 10.1073/pnas.0811212106] [Cited by in Crossref: 194] [Cited by in F6Publishing: 184] [Article Influence: 13.9] [Reference Citation Analysis]
204 Ma N, Jin J, Lu F, Woodgett J, Liu F. The role of protein kinase B (PKB) in modulating heat sensitivity in a human breast cancer cell line. International Journal of Radiation Oncology*Biology*Physics 2001;50:1041-50. [DOI: 10.1016/s0360-3016(01)01596-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
205 Antal CE, Newton AC. Spatiotemporal dynamics of phosphorylation in lipid second messenger signaling. Mol Cell Proteomics 2013;12:3498-508. [PMID: 23788531 DOI: 10.1074/mcp.R113.029819] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
206 Yang YC, Ho TC, Chen SL, Lai HY, Wu JY, Tsao YP. Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line. BMC Cancer 2007;7:216. [PMID: 18021457 DOI: 10.1186/1471-2407-7-216] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
207 Chen Y, Ohki R. p53-PHLDA3-Akt Network: The Key Regulators of Neuroendocrine Tumorigenesis. Int J Mol Sci 2020;21:E4098. [PMID: 32521808 DOI: 10.3390/ijms21114098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
208 Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, Bell DW. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011;17:1331-40. [PMID: 21266528 DOI: 10.1158/1078-0432.CCR-10-0540] [Cited by in Crossref: 169] [Cited by in F6Publishing: 99] [Article Influence: 15.4] [Reference Citation Analysis]
209 Zhang Q, Claret FX. Phosphatases: the new brakes for cancer development? Enzyme Res. 2012;2012:659649. [PMID: 22121480 DOI: 10.1155/2012/659649] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
210 Hostetter G, Kim SY, Savage S, Gooden GC, Barrett M, Zhang J, Alla L, Watanabe A, Einspahr J, Prasad A, Nickoloff BJ, Carpten J, Trent J, Alberts D, Bittner M. Random DNA fragmentation allows detection of single-copy, single-exon alterations of copy number by oligonucleotide array CGH in clinical FFPE samples. Nucleic Acids Res 2010;38:e9. [PMID: 19875416 DOI: 10.1093/nar/gkp881] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
211 Grønbæk K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-jensen K, Guldberg P. Somatic Fas Mutations in Non-Hodgkin’s Lymphoma: Association With Extranodal Disease and Autoimmunity. Blood 1998;92:3018-24. [DOI: 10.1182/blood.v92.9.3018] [Cited by in Crossref: 222] [Article Influence: 9.3] [Reference Citation Analysis]
212 Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA. 1999;96:1563-1568. [PMID: 9990064 DOI: 10.1073/pnas.96.4.1563] [Cited by in Crossref: 708] [Cited by in F6Publishing: 653] [Article Influence: 30.8] [Reference Citation Analysis]
213 Chen P, Dey P. Co-dependencies in the tumor immune microenvironment. Oncogene 2022. [PMID: 35817840 DOI: 10.1038/s41388-022-02406-7] [Reference Citation Analysis]
214 Frigo DE, Sherk AB, Wittmann BM, Norris JD, Wang Q, Joseph JD, Toner AP, Brown M, McDonnell DP. Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. Mol Endocrinol 2009;23:1385-96. [PMID: 19460858 DOI: 10.1210/me.2009-0010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
215 Kang Y, Lee HS, Kim WH. Promoter Methylation and Silencing of PTEN in Gastric Carcinoma. Lab Invest 2002;82:285-91. [DOI: 10.1038/labinvest.3780422] [Cited by in Crossref: 148] [Cited by in F6Publishing: 154] [Article Influence: 7.4] [Reference Citation Analysis]
216 Davies EM, Sheffield DA, Tibarewal P, Fedele CG, Mitchell CA, Leslie NR. The PTEN and Myotubularin Phosphoinositide 3-Phosphatases: Linking Lipid Signalling to Human Disease. In: Balla T, Wymann M, York JD, editors. Phosphoinositides I: Enzymes of Synthesis and Degradation. Dordrecht: Springer Netherlands; 2012. pp. 281-336. [DOI: 10.1007/978-94-007-3012-0_8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
217 Wu CW, Kao HL, Li AF, Chi CW, Lin WC. Protein tyrosine-phosphatase expression profiling in gastric cancer tissues. Cancer Lett 2006;242:95-103. [PMID: 16338072 DOI: 10.1016/j.canlet.2005.10.046] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
218 Kalkat M, De Melo J, Hickman KA, Lourenco C, Redel C, Resetca D, Tamachi A, Tu WB, Penn LZ. MYC Deregulation in Primary Human Cancers. Genes (Basel) 2017;8:E151. [PMID: 28587062 DOI: 10.3390/genes8060151] [Cited by in Crossref: 146] [Cited by in F6Publishing: 120] [Article Influence: 29.2] [Reference Citation Analysis]
219 Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44:685-689. [PMID: 22610119 DOI: 10.1038/ng.2279] [Cited by in Crossref: 958] [Cited by in F6Publishing: 888] [Article Influence: 95.8] [Reference Citation Analysis]
220 Hang Y, Zheng YC, Cao Y, Li QS, Sui YJ. Suppression of gastric cancer growth by adenovirus-mediated transfer of the PTEN gene. World J Gastroenterol 2005; 11(15): 2224-2229 [PMID: 15818730 DOI: 10.3748/wjg.v11.i15.2224] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
221 Flaherty DM, Monick MM, Hinde SL. Human Alveolar Macrophages Are Deficient in PTEN. Journal of Biological Chemistry 2006;281:5058-64. [DOI: 10.1074/jbc.m508997200] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
222 Rocha BR, Colli SDR, Barcelos LM, Gregório BM, Sampaio FJB. Age-dependent expression of Pten and Smad4 genes in the urogenital system of Wistar rats. Acta Cir Bras 2014;29:34-8. [DOI: 10.1590/s0102-86502014001300007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
223 Wright SCE, Vasilevski N, Serra V, Rodon J, Eichhorn PJA. Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. Cancers (Basel) 2021;13:1538. [PMID: 33810522 DOI: 10.3390/cancers13071538] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
224 Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445-1453. [PMID: 17456751 DOI: 10.2353/ajpath.2007.070011] [Cited by in Crossref: 895] [Cited by in F6Publishing: 790] [Article Influence: 59.7] [Reference Citation Analysis]
225 Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW, Lugo TG, Huang HJ, Cavenee WK. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci USA. 1998;95:9418-9423. [PMID: 9689095 DOI: 10.1073/pnas.95.16.9418] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 2.7] [Reference Citation Analysis]
226 Dhar S, Kumar A, Li K, Tzivion G, Levenson AS. Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2015;1853:265-75. [DOI: 10.1016/j.bbamcr.2014.11.004] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 9.9] [Reference Citation Analysis]
227 De Vivo I, Gertig DM, Nagase S, Hankinson SE, O'Brien R, Speizer FE, Parsons R, Hunter DJ. Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers. J Med Genet 2000;37:336-41. [PMID: 10807691 DOI: 10.1136/jmg.37.5.336] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
228 Caillet-Saguy C, Maisonneuve P, Delhommel F, Terrien E, Babault N, Lafon M, Cordier F, Wolff N. Strategies to interfere with PDZ-mediated interactions in neurons: What we can learn from the rabies virus. Prog Biophys Mol Biol 2015;119:53-9. [PMID: 25748547 DOI: 10.1016/j.pbiomolbio.2015.02.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
229 Sherman S, Shats O, Fleissner E, Bascom G, Yiee K, Copur M, Crow K, Rooney J, Mateen Z, Ketcham MA, Feng J, Sherman A, Gleason M, Kinarsky L, Silva-Lopez E, Edney J, Reed E, Berger A, Cowan K. Multicenter breast cancer collaborative registry. Cancer Inform 2011;10:217-26. [PMID: 21918596 DOI: 10.4137/CIN.S7845] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
230 Fog CK, Jensen KT, Lund AH. Chromatin-modifying proteins in cancer. APMIS 2007;115:1060-89. [PMID: 18042144 DOI: 10.1111/j.1600-0463.2007.apm_776.xml.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
231 Wang Q, Feng Y, Peng W, Ji D, Zhang Z, Qian W, Li J, Gu Q, Zhang D, Tang J, Zhang C, Wang S, Fu Z, Sun Y. Long noncoding RNA Linc02023 regulates PTEN stability and suppresses tumorigenesis of colorectal cancer in a PTEN-dependent pathway. Cancer Letters 2019;451:68-78. [DOI: 10.1016/j.canlet.2019.02.041] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
232 Thyssen G, Li TH, Lehmann L, Zhuo M, Sharma M, Sun Z. LZTS2 is a novel beta-catenin-interacting protein and regulates the nuclear export of beta-catenin. Mol Cell Biol 2006;26:8857-67. [PMID: 17000760 DOI: 10.1128/MCB.01031-06] [Cited by in Crossref: 46] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
233 Wang SE, Lin RJ. MicroRNA and HER2-overexpressing cancer. Microrna 2013;2:137-47. [PMID: 25070783 DOI: 10.2174/22115366113029990011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
234 Jin Z, Jia B, Fu Y, Tan L, Chen Q, Jiang P, Liu Y. Ligands of the peroxisome proliferator-activated receptor γ inhibit hepatoce llular carcinoma cell proliferation. Oncol Lett 2017;14:4767-71. [PMID: 28943966 DOI: 10.3892/ol.2017.6731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
235 Bleeker FE, Lamba S, Zanon C, van Tilborg AA, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Bardelli A. Absence of AKT1 mutations in glioblastoma. PLoS One 2009;4:e5638. [PMID: 19461960 DOI: 10.1371/journal.pone.0005638] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
236 Kohno T, Kawanishi M, Matsuda S, Ichikawa H, Takada M, Ohki M, Yamamoto T, Yokota J. Homozygous deletion and frequent allelic loss of the 21q11.1-q21.1 region including theANA gene in human lung carcinoma. Genes Chromosom Cancer 1998;21:236-43. [DOI: 10.1002/(sici)1098-2264(199803)21:3<236::aid-gcc8>3.0.co;2-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
237 Yu J, Zhang H, Gu J, Lin S, Li J, Lu W, Wang Y, Zhu J. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer. 2004;4:65. [PMID: 15367334 DOI: 10.1186/1471-2407-4-65] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 5.2] [Reference Citation Analysis]
238 Vijayakrishnapillai LMK, Desmarais JS, Groeschen MN, Perlin MH. Deletion of ptn1, a PTEN/TEP1 Orthologue, in Ustilago maydis Reduces Pathogenicity and Teliospore Development. J Fungi (Basel) 2018;5:E1. [PMID: 30577430 DOI: 10.3390/jof5010001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
239 Zhang B, Cao J, Zhou Q, Chen JY, Zou XP. Correlation between PTEN protein expression and clinicopathological features in the precancerous lesions and early gastric cancer. Shijie Huaren Xiaohua Zazhi 2008; 16(32): 3626-3630 [DOI: 10.11569/wcjd.v16.i32.3626] [Reference Citation Analysis]
240 Khan I, Ansari IA, Singh P, Dass J FP. Prediction of functionally significant single nucleotide polymorphisms in PTEN tumor suppressor gene: An in silico approach. Biotechnol Appl Biochem 2017;64:657-66. [PMID: 26800850 DOI: 10.1002/bab.1483] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
241 Hu PJ, Xu J, Ruvkun G. Two membrane-associated tyrosine phosphatase homologs potentiate C. elegans AKT-1/PKB signaling. PLoS Genet 2006;2:e99. [PMID: 16839187 DOI: 10.1371/journal.pgen.0020099] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
242 Lange F, Venus J, Shams Esfand Abady D, Porath K, Einsle A, Sellmann T, Neubert V, Reichart G, Linnebacher M, Köhling R, Kirschstein T. Galvanotactic Migration of Glioblastoma and Brain Metastases Cells. Life 2022;12:580. [DOI: 10.3390/life12040580] [Reference Citation Analysis]
243 Bi L, Yan X, Yang Y, Qian L, Tian Y, Mao JH, Chen W. The component formula of Salvia miltiorrhiza and Panax ginseng induces apoptosis and inhibits cell invasion and migration through targeting PTEN in lung cancer cells. Oncotarget. 2017;8:101599-101613. [PMID: 29254189 DOI: 10.18632/oncotarget.21354] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
244 Hallal S, Ebrahim Khani S, Wei H, Lee MYT, Sim HW, Sy J, Shivalingam B, Buckland ME, Alexander-Kaufman KL. Deep Sequencing of Small RNAs from Neurosurgical Extracellular Vesicles Substantiates miR-486-3p as a Circulating Biomarker that Distinguishes Glioblastoma from Lower-Grade Astrocytoma Patients. Int J Mol Sci 2020;21:E4954. [PMID: 32668808 DOI: 10.3390/ijms21144954] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
245 Zhang R, Banik NL, Ray SK. Combination of all-trans retinoic acid and interferon-gamma upregulated p27(kip1) and down regulated CDK2 to cause cell cycle arrest leading to differentiation and apoptosis in human glioblastoma LN18 (PTEN-proficient) and U87MG (PTEN-deficient) cells. Cancer Chemother Pharmacol. 2008;62:407-416. [PMID: 17960384 DOI: 10.1007/s00280-007-0619-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
246 Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol. 1998;8:1169-1178. [PMID: 9799734 DOI: 10.1016/s0960-9822(07)00488-5] [Cited by in Crossref: 555] [Cited by in F6Publishing: 265] [Article Influence: 23.1] [Reference Citation Analysis]
247 Strome ED, Wu X, Kimmel M, Plon SE. Heterozygous screen in Saccharomyces cerevisiae identifies dosage-sensitive genes that affect chromosome stability. Genetics 2008;178:1193-207. [PMID: 18245329 DOI: 10.1534/genetics.107.084103] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
248 Oldridge EE, Pellacani D, Collins AT, Maitland NJ. Prostate cancer stem cells: are they androgen-responsive? Mol Cell Endocrinol 2012;360:14-24. [PMID: 21802490 DOI: 10.1016/j.mce.2011.07.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
249 Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011;29:742-749. [PMID: 21804560 DOI: 10.1038/nbt.191] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
250 Wu W, Jing D, Meng Z, Hu B, Zhong B, Deng X, Jin X, Shao Z. FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity. Theranostics 2020;10:2859-71. [PMID: 32194840 DOI: 10.7150/thno.41279] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
251 Filtz EA, Emery A, Lu H, Forster CL, Karasch C, Hallstrom TC. Rb1 and Pten Co-Deletion in Osteoblast Precursor Cells Causes Rapid Lipoma Formation in Mice. PLoS One 2015;10:e0136729. [PMID: 26317218 DOI: 10.1371/journal.pone.0136729] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
252 Hensley PJ, Kyprianou N. Modeling prostate cancer in mice: limitations and opportunities. J Androl 2012;33:133-44. [PMID: 21680808 DOI: 10.2164/jandrol.111.013987] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
253 Premkumar DR, Jane EP, DiDomenico JD, Vukmer NA, Agostino NR, Pollack IF. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. J Pharmacol Exp Ther 2012;341:859-72. [PMID: 22393246 DOI: 10.1124/jpet.112.191536] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
254 Mueller WC, von Deimling A. Gene Regulation by Methylation. In: von Deimling A, editor. Gliomas. Berlin: Springer Berlin Heidelberg; 2009. pp. 217-39. [DOI: 10.1007/978-3-540-31206-2_13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
255 Terry G, Ho L, Londesborough P, Cross P, Lopes A, Monaghan J, Cuzick J. The role of human papillomavirus type 16 and the fragile histidine triad gene in the outcome of cervical neoplastic lesions. Br J Cancer 2004;91:2056-62. [PMID: 15570308 DOI: 10.1038/sj.bjc.6602253] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
256 Di Loreto C, Tell G, Pestrin M, Pandolfi M, Damante G, Puglisi F. PTEN and Egr-1 expression in thyroid proliferative lesions. Cancer Lett 2005;224:105-9. [PMID: 15911105 DOI: 10.1016/j.canlet.2004.10.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
257 Itoh T, Ishihara H, Shibasaki Y, Oka Y, Takenawa T. Autophosphorylation of Type I Phosphatidylinositol Phosphate Kinase Regulates Its Lipid Kinase Activity. Journal of Biological Chemistry 2000;275:19389-94. [DOI: 10.1074/jbc.m000426200] [Cited by in Crossref: 37] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
258 Shiraishi T, Tabuchi K. Genetic alterations of human brain tumors as molecular prognostic factors. Neuropathology 2003;23:95-108. [DOI: 10.1046/j.1440-1789.2003.00477.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
259 Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, Brugge JS. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012;21:227-39. [PMID: 22340595 DOI: 10.1016/j.ccr.2011.12.024] [Cited by in Crossref: 285] [Cited by in F6Publishing: 294] [Article Influence: 28.5] [Reference Citation Analysis]
260 Zhou XM, Sun R, Luo DH, Sun J, Zhang MY, Wang MH, Yang Y, Wang HY, Mai SJ. Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway. Oncotarget 2016;7:13634-50. [PMID: 26872369 DOI: 10.18632/oncotarget.7215] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
261 Liu Z, Li J, Li J, Huang J, Ke F, Qi Q, Jiang X, Zhong Z. Mannan-modified Ad5-PTEN treatment combined with docetaxel improves the therapeutic effect in H22 tumor-bearing mice. Int J Nanomedicine 2012;7:5039-49. [PMID: 23055722 DOI: 10.2147/IJN.S34022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
262 Liu Y, Boukhelifa M, Tribble E, Bankaitis VA. Functional studies of the mammalian Sac1 phosphoinositide phosphatase. Adv Enzyme Regul 2009;49:75-86. [PMID: 19534026 DOI: 10.1016/j.advenzreg.2009.01.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
263 Wan X, Yokoyama Y, Shinohara A, Takahashi Y, Tamaya T. PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway. Cell Death Differ 2002;9:414-20. [DOI: 10.1038/sj.cdd.4400982] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
264 Lambert LA, Whyteside AR, Turner AJ, Usmani BA. Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion. Br J Cancer 2008;99:1114-20. [PMID: 18781169 DOI: 10.1038/sj.bjc.6604631] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
265 Chen Y, Tergaonkar V. LncRNAs: Master Regulators in Disease and Cancer. Proc Singapore Natl Acad Sci 2020;14:79-89. [DOI: 10.1142/s2591722620400062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Knillová J, Kolář Z, Hlobilková A. THE SIGNIFICANCE OF KEY REGULATORS OF APOPTOSIS IN THE DEVELOPMENT AND PROGNOSIS OF PROSTATE CARCINOMA. II. PRODUCTS OF SUPPRESSOR GENES RB AND PTEN, CDKI, FAS. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003;147:11-7. [DOI: 10.5507/bp.2003.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
267 Wang Z, Li Y, Wu D, Yu S, Wang Y, Leung Chan F. Nuclear receptor HNF4α performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence. Oncogene 2020;39:1572-89. [PMID: 31695151 DOI: 10.1038/s41388-019-1080-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
268 Huang Q, Zhang QB, Dong J, Wu YY, Shen YT, Zhao YD, Zhu YD, Diao Y, Wang AD, Lan Q. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. BMC Cancer 2008;8:304. [PMID: 18940013 DOI: 10.1186/1471-2407-8-304] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 5.1] [Reference Citation Analysis]
269 Custodio AB, González-larriba JL, Bobokova J, Calles A, Álvarez R, Cuadrado E, Manzano A, Díaz-rubio E. Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early-Stage Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2009;4:891-910. [DOI: 10.1097/jto.0b013e3181a4b8fb] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
270 Mawrin C, Kirches E, Boltze C, Dietzmann K. PTEN is not altered in sporadic vestibular schwannomas: PTEN in schwannomas. Histopathology 2002;40:526-30. [DOI: 10.1046/j.1365-2559.2002.01398.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
271 Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000;20:5010-8. [PMID: 10866658 DOI: 10.1128/MCB.20.14.5010-5018.2000] [Cited by in Crossref: 548] [Cited by in F6Publishing: 281] [Article Influence: 24.9] [Reference Citation Analysis]
272 Macwhinnie N, Monaghan H. The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma. Int J Gynecol Cancer 2004;14:938-46. [PMID: 15361207 DOI: 10.1111/j.1048-891X.2004.14533.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
273 Moritake H, Horii Y, Kuroda H, Sugimoto T. Analysis of PTEN/MMAC1 alteration in neuroblastoma. Cancer Genet Cytogenet 2001;125:151-5. [PMID: 11369059 DOI: 10.1016/s0165-4608(00)00378-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
274 Zeng N, Bayan JA, He L, Stiles B. The Role of PTEN in β-Cell Growth. Open Endocrinol J 2010;4:23-32. [PMID: 23853672 DOI: 10.2174/1874216501004010023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
275 Hu YC, Lam KY, Tang JC, Srivastava G. Mutational analysis of the PTEN/MMAC1 gene in primary oesophageal squamous cell carcinomas. Mol Pathol 1999;52:353-6. [PMID: 10748870 DOI: 10.1136/mp.52.6.353] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
276 Igawa T, Lin FF, Rao P, Lin MF. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase. Prostate 2003;55:247-58. [PMID: 12712404 DOI: 10.1002/pros.10240] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
277 Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res 2010;70:453-62. [PMID: 20068170 DOI: 10.1158/0008-5472.CAN-09-2189] [Cited by in Crossref: 93] [Cited by in F6Publishing: 70] [Article Influence: 7.8] [Reference Citation Analysis]
278 Xiang SY, Dusaban SS, Brown JH. Lysophospholipid receptor activation of RhoA and lipid signaling pathways. Biochim Biophys Acta. 2013;1831:213-222. [PMID: 22986288 DOI: 10.1016/j.bbalip.2012.09.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
279 Yamamoto N, Mizoe J, Numasawa H, Tsujii H, Shibahara T, Noma H. Allelic loss on chromosomes 2q, 3p and 21q: possibly a poor prognostic factor in oral squamous cell carcinoma. Oral Oncology 2003;39:796-805. [DOI: 10.1016/s1368-8375(03)00079-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
280 Wang C, Ma J, Zhang N, Yang Q, Jin Y, Wang Y. The acetyl-CoA carboxylase enzyme: a target for cancer therapy? Expert Rev Anticancer Ther 2015;15:667-76. [PMID: 25979092 DOI: 10.1586/14737140.2015.1038246] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
281 Yang Y, Xu W, Liu D, Ding X, Su B, Sun Y, Gao W. PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy. Tumour Biol 2016;37:7785-96. [PMID: 26695147 DOI: 10.1007/s13277-015-4651-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
282 Fernandis AZ, Wenk MR. Lipid-based biomarkers for cancer. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:2830-5. [PMID: 19570730 DOI: 10.1016/j.jchromb.2009.06.015] [Cited by in Crossref: 85] [Cited by in F6Publishing: 61] [Article Influence: 6.5] [Reference Citation Analysis]
283 Kumagai T, O'Kelly J, Said JW, Koeffler HP. Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst 2003;95:896-905. [PMID: 12813173 DOI: 10.1093/jnci/95.12.896] [Cited by in Crossref: 92] [Cited by in F6Publishing: 69] [Article Influence: 4.8] [Reference Citation Analysis]
284 Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, Arroyo CD, Olvera N, King TA. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol 2010;18:371-4. [PMID: 20216404 DOI: 10.1097/PAI.0b013e3181d50bd5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
285 Abdulkadir SA, Kim J. Genetically engineered murine models of prostate cancer: insights into mechanisms of tumorigenesis and potential utility. Future Oncology 2005;1:351-60. [DOI: 10.1517/14796694.1.3.351] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
286 Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA. 1999;96:10182-10187. [PMID: 10468583 DOI: 10.1073/pnas.96.18.10182] [Cited by in Crossref: 219] [Cited by in F6Publishing: 229] [Article Influence: 9.5] [Reference Citation Analysis]
287 Wang S, Tie J, Wang R, Hu F, Gao L, Wang W, Wang L, Li Z, Hu S, Tang S, Li M, Wang X, Nie Y, Wu K, Fan D. SOX2, a predictor of survival in gastric cancer, inhibits cell proliferation and metastasis by regulating PTEN. Cancer Lett 2015;358:210-9. [PMID: 25543086 DOI: 10.1016/j.canlet.2014.12.045] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
288 Xi Y, Chen Y. Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies: PTENLOSS IN BONE MALIGNANCIES. J Cell Biochem 2015;116:1837-47. [DOI: 10.1002/jcb.25159] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
289 Gan W, Dai X, Lunardi A, Li Z, Inuzuka H, Liu P, Varmeh S, Zhang J, Cheng L, Sun Y, Asara JM, Beck AH, Huang J, Pandolfi PP, Wei W. SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Mol Cell 2015;59:917-30. [PMID: 26344095 DOI: 10.1016/j.molcel.2015.07.026] [Cited by in Crossref: 116] [Cited by in F6Publishing: 111] [Article Influence: 16.6] [Reference Citation Analysis]
290 Ratnacaram CK, Teletin M, Jiang M, Meng X, Chambon P, Metzger D. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc Natl Acad Sci U S A 2008;105:2521-6. [PMID: 18268330 DOI: 10.1073/pnas.0712021105] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 5.1] [Reference Citation Analysis]
291 van Duijn PW, Trapman J. PI3K/Akt signaling regulates p27kip1 expression via Skp2 in PC3 and DU145 prostate cancer cells, but is not a major factor in p27kip1 regulation in LNCaP and PC346 cells. Prostate 2006;66:749-60. [DOI: 10.1002/pros.20398] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
292 Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 2001;20:1287-99. [PMID: 11313873 DOI: 10.1038/sj.onc.1204257] [Cited by in Crossref: 186] [Cited by in F6Publishing: 170] [Article Influence: 8.9] [Reference Citation Analysis]
293 Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF. Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol 2012;355:135-69. [PMID: 22015553 DOI: 10.1007/82_2011_178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
294 Günzl P, Schabbauer G. Recent advances in the genetic analysis of PTEN and PI3K innate immune properties. Immunobiology. 2008;213:759-765. [PMID: 18926291 DOI: 10.1016/j.imbio.2008.07.028] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
295 Gustin JA, Maehama T, Dixon JE, Donner DB. The PTEN tumor suppressor protein inhibits tumor necrosis factor-induced nuclear factor kappa B activity. J Biol Chem 2001;276:27740-4. [PMID: 11356844 DOI: 10.1074/jbc.M102559200] [Cited by in Crossref: 83] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
296 Murakami A, Ohigashi H, Koshimizu K. Chemoprevention: Insights into biological mechanisms and promising food factors. Food Reviews International 1999;15:335-95. [DOI: 10.1080/87559129909541194] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
297 Simons AL, Orcutt KP, Madsen JM, Scarbrough PM, Spitz DR. The Role of Akt Pathway Signaling in Glucose Metabolism and Metabolic Oxidative Stress. In: Spitz DR, Dornfeld KJ, Krishnan K, Gius D, editors. Oxidative Stress in Cancer Biology and Therapy. Totowa: Humana Press; 2012. pp. 21-46. [DOI: 10.1007/978-1-61779-397-4_2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
298 Lee C, Kim JS, Waldman T. PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells. Cancer Res 2004;64:6906-14. [PMID: 15466180 DOI: 10.1158/0008-5472.CAN-04-1767] [Cited by in Crossref: 74] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
299 Raufi A, Alsharedi M, Khelfa Y, Tirona M. Bilateral Triple-Negative Invasive Breast Cancer with a BRCA2 Mutation, and Glioblastoma: A Case Report and Literature Review. J Breast Cancer 2017;20:108-11. [PMID: 28382102 DOI: 10.4048/jbc.2017.20.1.108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
300 Khan KH, Yap TA, Yan L, Cunningham D. Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer 2013;32:253-65. [PMID: 23642907 DOI: 10.5732/cjc.013.10057] [Cited by in Crossref: 108] [Cited by in F6Publishing: 110] [Article Influence: 13.5] [Reference Citation Analysis]
301 Figer A, Kaplan A, Frydman M, Lev D, Paswell J, Papa MZ, Goldman B, Friedman E. Germline mutations in the PTEN gene in Israeli patients with Bannayan-Riley-Ruvalcaba syndrome and women with familial breast cancer. Clin Genet 2002;62:298-302. [PMID: 12372056 DOI: 10.1034/j.1399-0004.2002.620407.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
302 van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011;34:71-88. [PMID: 21336636 DOI: 10.1007/s13402-011-0010-3] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 7.3] [Reference Citation Analysis]
303 Welcsh PL, Schubert EL, King M. Inherited breast cancer: an emerging picture. Clinical Genetics 1998;54:447-58. [DOI: 10.1111/j.1399-0004.1998.tb03764.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
304 Castellino RC, Durden DL. Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol 2007;3:682-93. [PMID: 18046441 DOI: 10.1038/ncpneuro0661] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 5.6] [Reference Citation Analysis]
305 Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011;29:742-749. [PMID: 21804560 DOI: 10.1038/nbt.1914] [Cited by in Crossref: 704] [Cited by in F6Publishing: 677] [Article Influence: 64.0] [Reference Citation Analysis]
306 Achary PM, Zhao H, Fan Z, Gogineni S, Pulijaal VR, Herbst L, Mahadevia PS, Jones JG, Klinger HP, Vikram B. A candidate metastasis-associated DNA marker for ductal mammary carcinoma. Breast Cancer Res 2003;5:R52-8. [PMID: 12631399 DOI: 10.1186/bcr571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
307 Choorapoikayil S, Kuiper RV, de Bruin A, den Hertog J. Haploinsufficiency of the genes encoding the tumor suppressor Pten predisposes zebrafish to hemangiosarcoma. Dis Model Mech 2012;5:241-7. [PMID: 22071262 DOI: 10.1242/dmm.008326] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
308 Hobiger K, Friedrich T. Voltage sensitive phosphatases: emerging kinship to protein tyrosine phosphatases from structure-function research. Front Pharmacol 2015;6:20. [PMID: 25713537 DOI: 10.3389/fphar.2015.00020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
309 Ding X, Morrison G, Dean B, Hop CE, Tobler L, Percey S, Meng M, Reuschel S, West DA, Holden S, Ware JA. A solid phase extraction-liquid chromatographic-tandem mass spectrometry method for determination of concentrations of GDC-0941, a small molecule class I phosphatidylinositide 3-kinase inhibitor, to support clinical development. J Pharm Biomed Anal 2012;61:1-7. [PMID: 22169467 DOI: 10.1016/j.jpba.2011.11.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
310 Wang J, Xu W, He Y, Xia Q, Liu S. LncRNA MEG3 impacts proliferation, invasion, and migration of ovarian cancer cells through regulating PTEN. Inflamm Res 2018;67:927-36. [DOI: 10.1007/s00011-018-1186-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
311 Astbury C, Jackson-Cook CK, Culp SH, Paisley TE, Ware JL. Suppression of tumorigenicity in the human prostate cancer cell line M12 via microcell-mediated restoration of chromosome 19. Genes Chromosomes Cancer 2001;31:143-55. [PMID: 11319802 DOI: 10.1002/gcc.1128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
312 Cho YJ, Liang P. Killin is a p53-regulated nuclear inhibitor of DNA synthesis. Proc Natl Acad Sci U S A 2008;105:5396-401. [PMID: 18385383 DOI: 10.1073/pnas.0705410105] [Cited by in Crossref: 60] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
313 Depowski PL, Rosenthal SI, Ross JS. Loss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast Cancer. Mod Pathol 2001;14:672-6. [DOI: 10.1038/modpathol.3880371] [Cited by in Crossref: 190] [Cited by in F6Publishing: 186] [Article Influence: 9.0] [Reference Citation Analysis]
314 Yoo SB, Kim YJ, Kim H, Jin Y, Sun P, Jheon S, Lee JS, Chung J. Alteration of the E-cadherin/β-Catenin Complex Predicts Poor Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment. Ann Surg Oncol 2013;20:545-52. [DOI: 10.1245/s10434-013-2970-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
315 Carnell MJ, Insall RH. Actin on disease--studying the pathobiology of cell motility using Dictyostelium discoideum. Semin Cell Dev Biol 2011;22:82-8. [PMID: 21145982 DOI: 10.1016/j.semcdb.2010.12.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
316 Sun C, Zhao J, Jin Y, Hou C, Zong W, Lu T, Li H, Gao J. PTEN regulation of the proliferation and differentiation of auditory progenitors through the PTEN/PI3K/Akt-signaling pathway in mice. Neuroreport 2014;25:177-83. [PMID: 24481416 DOI: 10.1097/WNR.0000000000000069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
317 Pribat A, Sormani R, Rousseau-Gueutin M, Julkowska MM, Testerink C, Joubès J, Castroviejo M, Laguerre M, Meyer C, Germain V, Rothan C. A novel class of PTEN protein in Arabidopsis displays unusual phosphoinositide phosphatase activity and efficiently binds phosphatidic acid. Biochem J 2012;441:161-71. [PMID: 21864294 DOI: 10.1042/BJ20110776] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 2.9] [Reference Citation Analysis]
318 Piao S, Zheng L, Zheng H, Zhou M, Feng Q, Zhou S, Ke M, Yang H, Wang X, Wang F. High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration. Journal of Immunology Research 2022;2022:1-28. [DOI: 10.1155/2022/2922832] [Reference Citation Analysis]
319 Hlushchuk I, Barut J, Airavaara M, Luk K, Domanskyi A, Chmielarz P. Cell Culture Media, Unlike the Presence of Insulin, Affect α-Synuclein Aggregation in Dopaminergic Neurons. Biomolecules 2022;12:563. [DOI: 10.3390/biom12040563] [Reference Citation Analysis]
320 Tetzlaff MT, Teh BS, Timme TL, Fujita T, Satoh T, Tabata K, Mai W, Vlachaki MT, Amato RJ, Kadmon D, Miles BJ, Ayala G, Wheeler TM, Aguilar-cordova E, Thompson TC, Butler EB. Expanding the Therapeutic Index of Radiation Therapy by Combining In Situ Gene Therapy in the Treatment of Prostate Cancer. Technol Cancer Res Treat 2006;5:23-36. [DOI: 10.1177/153303460600500104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
321 Bridges D, Saltiel AR. Phosphoinositides: Key modulators of energy metabolism. Biochim Biophys Acta 2015;1851:857-66. [PMID: 25463477 DOI: 10.1016/j.bbalip.2014.11.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
322 El Sheikh SS, Domin J, Abel P, Stamp G, Lalani el-N. Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 2004;6:846-53. [PMID: 15720812 DOI: 10.1593/neo.04379] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
323 Sun H, Enomoto T, Fujita M, Wada H, Yoshino K, Ozaki K, Nakamura T, Murata Y. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol 2001;115:32-8. [PMID: 11190805 DOI: 10.1309/7JX6-B9U9-3P0R-EQNY] [Cited by in Crossref: 84] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
324 Rizvi MMA, Alam MS, Ali A, Mehdi SJ, Batra S, Mandal AK. Aberrant promoter methylation and inactivation of PTEN gene in cervical carcinoma from Indian population. J Cancer Res Clin Oncol 2011;137:1255-62. [DOI: 10.1007/s00432-011-0994-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
325 Zhou H, Huang S. The complexes of mammalian target of rapamycin. Curr Protein Pept Sci 2010;11:409-24. [PMID: 20491627 DOI: 10.2174/138920310791824093] [Cited by in Crossref: 84] [Cited by in F6Publishing: 80] [Article Influence: 7.6] [Reference Citation Analysis]
326 Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA. 1999;96:4240-4245. [PMID: 10200246 DOI: 10.1073/pnas.96.8.4240] [Cited by in Crossref: 1395] [Cited by in F6Publishing: 1325] [Article Influence: 60.7] [Reference Citation Analysis]
327 DeAngelis T, Morrione A, Baserga R. Mutual interaction and reciprocal down-regulation between c-met and insulin receptor substrate-1. J Cell Physiol 2010;224:658-63. [PMID: 20578241 DOI: 10.1002/jcp.22164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
328 Zhang LY, Ho-Fun Lee V, Wong AM, Kwong DL, Zhu YH, Dong SS, Kong KL, Chen J, Tsao SW, Guan XY, Fu L. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis 2013;34:454-63. [PMID: 23125220 DOI: 10.1093/carcin/bgs346] [Cited by in Crossref: 136] [Cited by in F6Publishing: 130] [Article Influence: 13.6] [Reference Citation Analysis]
329 López-Otín C, Diamandis EP. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev. 1998;19:365-396. [PMID: 9715372 DOI: 10.1210/edrv.19.4.0337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 38] [Article Influence: 0.1] [Reference Citation Analysis]
330 Dillon LM, Miller TW. Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets 2014;15:65-79. [PMID: 24387334 DOI: 10.2174/1389450114666140106100909] [Cited by in Crossref: 140] [Cited by in F6Publishing: 125] [Article Influence: 17.5] [Reference Citation Analysis]
331 Kim JH, Han SY, Lee SW, Baek YH, Kim HY, Kim JH, Jeong JS, Roh YH, Kim YH, Park BH, Kwon HJ, Cho JH, Nam KJ. Sodium iodide symporter and phosphatase and tensin homolog deleted on chromosome ten expression in cholangiocarcinoma analysis with clinicopathological parameters. Gut Liver 2012;6:374-80. [PMID: 22844568 DOI: 10.5009/gnl.2012.6.3.374] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
332 Stebbing J, Lit LC, Zhang H, Darrington RS, Melaiu O, Rudraraju B, Giamas G. The regulatory roles of phosphatases in cancer. Oncogene. 2014;33:939-953. [PMID: 23503460 DOI: 10.1038/onc.2013.80] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 5.9] [Reference Citation Analysis]
333 Qi M, Anderson AE, Chen DZ, Sun S, Auborn KJ. Indole-3-carbinol prevents PTEN loss in cervical cancer in vivo. Mol Med 2005;11:59-63. [PMID: 16557333 DOI: 10.2119/2006-00007.Auborn] [Cited by in Crossref: 29] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
334 Koide S, Okazaki M, Tamura M, Ozumi K, Takatsu H, Kamezaki F, Tanimoto A, Tasaki H, Sasaguri Y, Nakashima Y, Otsuji Y. PTEN reduces cuff-induced neointima formation and proinflammatory cytokines. American Journal of Physiology-Heart and Circulatory Physiology 2007;292:H2824-31. [DOI: 10.1152/ajpheart.01221.2006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
335 Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, Bredel M. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. JAMA 2009;302:276-89. [PMID: 19602687 DOI: 10.1001/jama.2009.1022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
336 Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol. 2007;27:662-677. [PMID: 17060456 DOI: 10.1128/mcb.00537-06] [Cited by in Crossref: 112] [Cited by in F6Publishing: 79] [Article Influence: 7.0] [Reference Citation Analysis]
337 Berrie CP. Phosphoinositide 3-kinase inhibition in cancer treatment. Expert Opinion on Investigational Drugs 2005;10:1085-98. [DOI: 10.1517/13543784.10.6.1085] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
338 Üner AH, Sağlam A, Han Ü, Hayran M, Sungur A, Ruacan Ş. PTEN and p27 expression in mature T-cell and NK-cell neoplasms. Leukemia & Lymphoma 2009;46:1463-70. [DOI: 10.1080/10428190500144813] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
339 Zhang S, Taghibiglou C, Girling K, Dong Z, Lin SZ, Lee W, Shyu WC, Wang YT. Critical role of increased PTEN nuclear translocation in excitotoxic and ischemic neuronal injuries. J Neurosci 2013;33:7997-8008. [PMID: 23637190 DOI: 10.1523/JNEUROSCI.5661-12.2013] [Cited by in Crossref: 57] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
340 Papa A, Pandolfi PP. The PTEN⁻PI3K Axis in Cancer. Biomolecules 2019;9:E153. [PMID: 30999672 DOI: 10.3390/biom9040153] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 21.3] [Reference Citation Analysis]
341 Toyooka S, Ouchida M, Jitsumori Y, Tsukuda K, Sakai A, Nakamura A, Shimizu N, Shimizu K. HD-PTP: A novel protein tyrosine phosphatase gene on human chromosome 3p21.3. Biochem Biophys Res Commun 2000;278:671-8. [PMID: 11095967 DOI: 10.1006/bbrc.2000.3870] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 1.9] [Reference Citation Analysis]
342 Marsh DJ, Dahia PL, Caron S, Kum JB, Frayling IM, Tomlinson IP, Hughes KS, Eeles RA, Hodgson SV, Murday VA. Germline PTEN mutations in Cowden syndrome-like families. J Med Genet. 1998;35:881-885. [PMID: 9832031 DOI: 10.1136/jmg.35.11.881] [Cited by in Crossref: 101] [Cited by in F6Publishing: 86] [Article Influence: 4.4] [Reference Citation Analysis]
343 Cui X, Vivo ID, Slany R, Miyamoto A, Firestein R, Cleary ML. Association of SET domain and myotubularin-related proteins modulates growth control. Nat Genet 1998;18:331-7. [DOI: 10.1038/ng0498-331] [Cited by in Crossref: 165] [Cited by in F6Publishing: 160] [Article Influence: 6.9] [Reference Citation Analysis]
344 Qian J, Ling S, Castillo AC, Long B, Birnbaum Y, Ye Y. Regulation of phosphatase and tensin homolog on chromosome 10 in response to hypoxia. American Journal of Physiology-Heart and Circulatory Physiology 2012;302:H1806-17. [DOI: 10.1152/ajpheart.00929.2011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
345 Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66. [PMID: 17237035 DOI: 10.1016/j.bbcan.2007.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 13] [Article Influence: 0.1] [Reference Citation Analysis]
346 Hwang CC, Igase M, Okuda M, Coffey M, Noguchi S, Mizuno T. Reovirus changes the expression of anti-apoptotic and proapoptotic proteins with the c-kit downregulation in canine mast cell tumor cell lines. Biochem Biophys Res Commun 2019;517:233-7. [PMID: 31345575 DOI: 10.1016/j.bbrc.2019.07.050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
347 Watson SK, deLeeuw RJ, Horsman DE, Squire JA, Lam WL. Cytogenetically balanced translocations are associated with focal copy number alterations. Hum Genet 2007;120:795-805. [DOI: 10.1007/s00439-006-0251-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
348 Huang SH, Tseng JC, Lin CY, Kuo YY, Wang BJ, Kao YH, Muller CJF, Joubert E, Chuu CP. Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling. Phytomedicine 2019;64:153068. [PMID: 31419729 DOI: 10.1016/j.phymed.2019.153068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
349 Shin KH, Choe G, Park YJ, Jang JH, Jung HW, Park JG. Establishment and characterization of nine human brain tumor cell lines. In Vitro Cell Dev Biol Anim 2001;37:625-8. [PMID: 11776963 DOI: 10.1290/1071-2690(2001)037<0625:EACONH>2.0.CO;2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
350 Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate 2008;68:935-44. [PMID: 18386291 DOI: 10.1002/pros.20745] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
351 Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13:140-156. [PMID: 24481312 DOI: 10.1038/nrd4204] [Cited by in Crossref: 1026] [Cited by in F6Publishing: 954] [Article Influence: 128.3] [Reference Citation Analysis]
352 Trapasso F, Iuliano R, Boccia A, Stella A, Visconti R, Bruni P, Baldassarre G, Santoro M, Viglietto G, Fusco A. Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1). Mol Cell Biol 2000;20:9236-46. [PMID: 11094075 DOI: 10.1128/MCB.20.24.9236-9246.2000] [Cited by in Crossref: 74] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
353 Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, Louis DN, Chin L, DePinho RA. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci U S A 2008;105:10703-8. [PMID: 18669646 DOI: 10.1073/pnas.0712034105] [Cited by in Crossref: 96] [Cited by in F6Publishing: 97] [Article Influence: 6.9] [Reference Citation Analysis]
354 Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001;93:1246-56. [PMID: 11504770 DOI: 10.1093/jnci/93.16.1246] [Cited by in Crossref: 409] [Cited by in F6Publishing: 353] [Article Influence: 19.5] [Reference Citation Analysis]
355 Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene. 2002;21:2357-2364. [PMID: 11948419 DOI: 10.1038/sj.onc.1205296] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 2.4] [Reference Citation Analysis]
356 Yazdani Y, Farazmandfar T, Azadeh H, Zekavatian Z. The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: miR-21 and promoter methylation. J Biomed Sci 2016;23:9. [PMID: 26787105 DOI: 10.1186/s12929-016-0228-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
357 Hayes MN, Langenau DM. Discovering novel oncogenic pathways and new therapies using zebrafish models of sarcoma. Methods Cell Biol 2017;138:525-61. [PMID: 28129857 DOI: 10.1016/bs.mcb.2016.11.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
358 Lee Jr J, Mccubrey J. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 2002;16:486-507. [DOI: 10.1038/sj.leu.2402460] [Cited by in Crossref: 168] [Cited by in F6Publishing: 160] [Article Influence: 8.4] [Reference Citation Analysis]
359 Wang Q, Zhou Y, Wang X, Chung DH, Evers BM. Regulation of PTEN expression in intestinal epithelial cells by c-Jun NH2-terminal kinase activation and nuclear factor-kappaB inhibition. Cancer Res 2007;67:7773-81. [PMID: 17699782 DOI: 10.1158/0008-5472.CAN-07-0187] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
360 Chong X, Chen J, Zheng N, Zhou Z, Hai Y, Chen S, Zhang Y, Yu Q, Yu S, Chen Z, Bao W, Quan M, Chen ZS, Zhan Y, Gao Y. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN. Mol Cancer 2022;21:118. [PMID: 35619132 DOI: 10.1186/s12943-022-01531-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
361 Chen MW, Wu XJ. SLC25A22 Promotes Proliferation and Metastasis of Osteosarcoma Cells via the PTEN Signaling Pathway. Technol Cancer Res Treat 2018;17:1533033818811143. [PMID: 30482097 DOI: 10.1177/1533033818811143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
362 Bretón-Romero R, Kalwa H, Lamas S, Michel T. Role of PTEN in modulation of ADP-dependent signaling pathways in vascular endothelial cells. Biochim Biophys Acta 2013;1833:2586-95. [PMID: 23806663 DOI: 10.1016/j.bbamcr.2013.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
363 Ocana A, Vera-Badillo F, Al-Mubarak M, Templeton AJ, Corrales-Sanchez V, Diez-Gonzalez L, Cuenca-Lopez MD, Seruga B, Pandiella A, Amir E. Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS One. 2014;9:e95219. [PMID: 24777052 DOI: 10.1371/journal.pone.0095219] [Cited by in Crossref: 97] [Cited by in F6Publishing: 100] [Article Influence: 12.1] [Reference Citation Analysis]
364 Chen M, Nowak DG, Trotman LC. Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy. Clin Cancer Res 2014;20:3057-63. [PMID: 24928944 DOI: 10.1158/1078-0432.CCR-12-3680] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
365 Fritz WA, Lin TM, Peterson RE. The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates. Carcinogenesis 2008;29:1077-82. [PMID: 18359762 DOI: 10.1093/carcin/bgn069] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
366 Wang X, Jiang X. Post-translational regulation of PTEN. Oncogene 2008;27:5454-63. [PMID: 18794880 DOI: 10.1038/onc.2008.242] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 4.8] [Reference Citation Analysis]
367 Leube B, Drechsler M, Mühlmann K, Schäfer R, Schulz WA, Santourlidis S, Anastasiadis A, Ackermann R, Visakorpi T, Müller W, Royer-Pokora B. Refined mapping of allele loss at chromosome 10q23-26 in prostate cancer. Prostate 2002;50:135-44. [PMID: 11813205 DOI: 10.1002/pros.10038] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
368 Fragoso R, Barata JT. Kinases, tails and more: regulation of PTEN function by phosphorylation. Methods. 2015;77-78:75-81. [PMID: 25448482 DOI: 10.1016/j.ymeth.2014.10.015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
369 Du P, Huang P, Huang X, Li X, Feng Z, Li F, Liang S, Song Y, Stenvang J, Brünner N, Yang H, Ou Y, Gao Q, Li L. Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance. Sci Rep 2017;7:15324. [PMID: 29127303 DOI: 10.1038/s41598-017-14909-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
370 Van Aller GS, Carson JD, Tang W, Peng H, Zhao L, Copeland RA, Tummino PJ, Luo L. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. Biochem Biophys Res Commun 2011;406:194-9. [PMID: 21300025 DOI: 10.1016/j.bbrc.2011.02.010] [Cited by in Crossref: 101] [Cited by in F6Publishing: 87] [Article Influence: 9.2] [Reference Citation Analysis]
371 Mishra RR, Chaudhary JK, Bajaj GD, Rath PC. A novel human TPIP splice-variant (TPIP-C2) mRNA, expressed in human and mouse tissues, strongly inhibits cell growth in HeLa cells. PLoS One 2011;6:e28433. [PMID: 22164291 DOI: 10.1371/journal.pone.0028433] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
372 Verhagen PC, van Duijn PW, Hermans KG, Looijenga LH, van Gurp RJ, Stoop H, van der Kwast TH, Trapman J. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 2006;208:699-707. [PMID: 16402365 DOI: 10.1002/path.1929] [Cited by in Crossref: 78] [Cited by in F6Publishing: 62] [Article Influence: 4.9] [Reference Citation Analysis]
373 Wang L, Xu S, Yue W, Zhao X, Zhang L, Wang Y. [Expression and clinical significance of mTOR and PTEN in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2010;13:717-21. [PMID: 20673489 DOI: 10.3779/j.issn.1009-3419.2010.07.11] [Reference Citation Analysis]
374 Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 2006;19:238-45. [DOI: 10.1038/modpathol.3800525] [Cited by in Crossref: 136] [Cited by in F6Publishing: 120] [Article Influence: 8.0] [Reference Citation Analysis]
375 Collaud S, Tischler V, Atanassoff A, Wiedl T, Komminoth P, Oehlschlegel C, Weder W, Soltermann A. Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN. BMC Cancer 2015;15:74. [PMID: 25884169 DOI: 10.1186/s12885-015-1084-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
376 Kloth M, Buettner R. Changing histopathological diagnostics by genome-based tumor classification. Genes (Basel) 2014;5:444-59. [PMID: 24879454 DOI: 10.3390/genes5020444] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
377 Lu Z, Guo H, Lin Y, Shen L, Yin C, Xie S. Effects of PTEN gene silencing on invasion and EMT in oral squamous carcinoma Tca8113 cells. J Oral Pathol Med 2017;46:31-8. [DOI: 10.1111/jop.12461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
378 Li D, Qu Y, Mao M, Zhang X, Li J, Ferriero D, Mu D. Involvement of the PTEN-AKT-FOXO3a pathway in neuronal apoptosis in developing rat brain after hypoxia-ischemia. J Cereb Blood Flow Metab 2009;29:1903-13. [PMID: 19623194 DOI: 10.1038/jcbfm.2009.102] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 5.3] [Reference Citation Analysis]
379 Wang Y, Tong Z, Zhang W, Zhang W, Buzdin A, Mu X, Yan Q, Zhao X, Chang HH, Duhon M, Zhou X, Zhao G, Chen H, Li X. FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients. Front Oncol 2021;11:683419. [PMID: 34164344 DOI: 10.3389/fonc.2021.683419] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
380 Koganti R, Suryawanshi R, Shukla D. Heparanase, cell signaling, and viral infections. Cell Mol Life Sci 2020;77:5059-77. [PMID: 32462405 DOI: 10.1007/s00018-020-03559-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
381 Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, Zhao L, Denley A. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol 2010;347:79-104. [PMID: 20582532 DOI: 10.1007/82_2010_80] [Cited by in Crossref: 28] [Cited by in F6Publishing: 49] [Article Influence: 2.5] [Reference Citation Analysis]
382 Herfarth KK, Gutwein S, Debus J. Postoperative radiotherapy of astrocytomas. Semin Surg Oncol 2001;20:13-23. [DOI: 10.1002/ssu.1012] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
383 Lüder Ripoli F, Conradine Hammer S, Mohr A, Willenbrock S, Hewicker-Trautwein M, Brenig B, Murua Escobar H, Nolte I. Multiplex Gene Expression Profiling of 16 Target Genes in Neoplastic and Non-Neoplastic Canine Mammary Tissues Using Branched-DNA Assay. Int J Mol Sci 2016;17:E1589. [PMID: 27657059 DOI: 10.3390/ijms17091589] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
384 Palmini G, Marini F, Brandi ML. What Is New in the miRNA World Regarding Osteosarcoma and Chondrosarcoma? Molecules 2017;22:E417. [PMID: 28272374 DOI: 10.3390/molecules22030417] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
385 Yin D, Chen W, O'Kelly J, Lu D, Ham M, Doan NB, Xie D, Wang C, Vadgama J, Said JW, Black KL, Koeffler HP. Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int J Cancer 2010;127:2257-67. [PMID: 20162579 DOI: 10.1002/ijc.25257] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
386 Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773. [PMID: 19228619 DOI: 10.1056/nejmoa0808710] [Cited by in Crossref: 3515] [Cited by in F6Publishing: 2037] [Article Influence: 270.4] [Reference Citation Analysis]
387 Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, Koga T, Morita M, Kakeji Y, Maehara Y. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat 2007;101:249-57. [PMID: 17006756 DOI: 10.1007/s10549-006-9295-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
388 van Gisbergen PA, Li M, Wu SZ, Bezanilla M. Class II formin targeting to the cell cortex by binding PI(3,5)P(2) is essential for polarized growth. J Cell Biol 2012;198:235-50. [PMID: 22801781 DOI: 10.1083/jcb.201112085] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
389 Erdem HB, Bahsi T. Spectrum of germline cancer susceptibility gene mutations in Turkish colorectal cancer patients: a single center study. Turk J Med Sci 2020;50:1015-21. [PMID: 32283892 DOI: 10.3906/sag-2002-46] [Reference Citation Analysis]
390 Bian EB, Zhao B, Huang C, Wang H, Meng XM, Wu BM, Ma TT, Zhang L, Lv XW, Li J. New advances of DNA methylation in liver fibrosis, with special emphasis on the crosstalk between microRNAs and DNA methylation machinery. Cell Signal. 2013;25:1837-1844. [PMID: 23707524 DOI: 10.1016/j.cellsig.2013.05.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
391 Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009;8:403-13. [PMID: 19177005 DOI: 10.4161/cc.8.3.7555] [Cited by in F6Publishing: 61] [Reference Citation Analysis]
392 Kastrinakis NG, Gorgoulis VG, Foukas PG, Dimopoulos MA, Kittas C. Molecular aspects of multiple myeloma. Ann Oncol 2000;11:1217-28. [PMID: 11106109 DOI: 10.1023/a:1008331714186] [Cited by in Crossref: 54] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
393 Unoki M, Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 2001;20:4457-65. [PMID: 11494141 DOI: 10.1038/sj.onc.1204608] [Cited by in Crossref: 251] [Cited by in F6Publishing: 246] [Article Influence: 12.0] [Reference Citation Analysis]
394 Kawamura N, Nagai H, Bando K, Koyama M, Matsumoto S, Tajiri T, Onda M, Fujimoto J, Ueki T, Konishi N, Shiba T, Emi M. PTEN/MMAC1 mutations in hepatocellular carcinomas: somatic inactivation of both alleles in tumors. Jpn J Cancer Res 1999;90:413-8. [PMID: 10363579 DOI: 10.1111/j.1349-7006.1999.tb00763.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
395 Brauer PM, Tyner AL. RAKing in AKT: a tumor suppressor function for the intracellular tyrosine kinase FRK. Cell Cycle 2009;8:2728-32. [PMID: 19652529 DOI: 10.4161/cc.8.17.9389] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
396 Mitra S, Leonard WJ. Biology of IL-2 and its therapeutic modulation: Mechanisms and strategies. J Leukoc Biol 2018;103:643-55. [PMID: 29522246 DOI: 10.1002/JLB.2RI0717-278R] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 6.8] [Reference Citation Analysis]
397 Haddadi N, Travis G, Nassif NT, Simpson AM, Marsh DJ. Toward Systems Pathology for PTEN Diagnostics. Cold Spring Harb Perspect Med 2020;10:a037127. [PMID: 31615872 DOI: 10.1101/cshperspect.a037127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
398 Yakubov E, Ghoochani A, Buslei R, Buchfelder M, Eyüpoglu IY, Savaskan N. Hidden association of Cowden syndrome, PTEN mutation and meningioma frequency. Oncoscience 2016;3:149-55. [PMID: 27489861 DOI: 10.18632/oncoscience.305] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
399 Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 1999;99:323-334. [PMID: 10555148 DOI: 10.1016/s0092-8674(00)81663-3] [Cited by in Crossref: 730] [Cited by in F6Publishing: 376] [Article Influence: 31.7] [Reference Citation Analysis]
400 Zhang ZY. Mechanistic studies on protein tyrosine phosphatases. Prog Nucleic Acid Res Mol Biol. 2003;73:171-220. [PMID: 12882518 DOI: 10.1016/S0079-6603(03)01006-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
401 Hsu F, Mao Y. The structure of phosphoinositide phosphatases: Insights into substrate specificity and catalysis. Biochim Biophys Acta 2015;1851:698-710. [PMID: 25264170 DOI: 10.1016/j.bbalip.2014.09.015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
402 Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L. PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts. J Neurooncol 2011;104:155-67. [PMID: 21188471 DOI: 10.1007/s11060-010-0492-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
403 Suri V, Das P, Pathak P, Jain A, Sharma MC, Borkar SA, Suri A, Gupta D, Sarkar C. Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro Oncol 2009;11:274-80. [PMID: 18981259 DOI: 10.1215/15228517-2008-092] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 4.9] [Reference Citation Analysis]
404 D’arcangelo G. From human tissue to animal models: Insights into the pathogenesis of cortical dysplasia. Epilepsia 2009;50:28-33. [DOI: 10.1111/j.1528-1167.2009.02290.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
405 Yu C, Zhang B, Li Y, Yu X. SIX1 reduces the expression of PTEN via activating PI3K/AKT signal to promote cell proliferation and tumorigenesis in osteosarcoma. Biomedicine & Pharmacotherapy 2018;105:10-7. [DOI: 10.1016/j.biopha.2018.04.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
406 Nabhan C, Parsons B, Touloukian EZ, Stadler WM. Novel approaches and future directions in castration-resistant prostate cancer. Ann Oncol 2011;22:1948-57. [PMID: 21252057 DOI: 10.1093/annonc/mdq639] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
407 Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG. Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 2004;70:229-43. [PMID: 15674480 DOI: 10.1007/s11060-004-2752-5] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 5.9] [Reference Citation Analysis]
408 Gesk S, Siebert R, Wacker HH, Nürnberg N, Harder L, Lehman J, Klöppel G, Grote W, Stöckle M, Schlegelberger B. Lack of deletions of the PTEN/MMAC1 and MXI1 loci in renal cell carcinoma by interphase cytogenetics. Cancer Genet Cytogenet 2000;118:87-8. [PMID: 10766523 DOI: 10.1016/s0165-4608(99)00190-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
409 Zhan H, Bai Y, Lv Y, Zhang X, Zhang L, Deng S. Pharmacological mechanism of mylabris in the treatment of leukemia based on bioinformatics and systematic pharmacology. Bioengineered 2021;12:3229-39. [PMID: 34224300 DOI: 10.1080/21655979.2021.1943110] [Reference Citation Analysis]
410 Tu W, You L, Tsou A, Chen C. Pten Haplodeficiency Accelerates Liver Tumor Growth in miR-122a–Null Mice via Expansion of Periportal Hepatocyte-Like Cells. The American Journal of Pathology 2018;188:2688-702. [DOI: 10.1016/j.ajpath.2018.07.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
411 Rohrschneider LR, Fuller JF, Wolf I, Liu Y, Lucas DM. Structure, function, and biology of SHIP proteins. Genes Dev 2000;14:505-20. [DOI: 10.1101/gad.14.5.505] [Cited by in Crossref: 95] [Cited by in F6Publishing: 3] [Article Influence: 4.3] [Reference Citation Analysis]
412 Poetsch M, Dittberner T, Woenckhaus C. PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genet Cytogenet. 2001;125:21-26. [PMID: 11297763 DOI: 10.1016/s0165-4608(00)00353-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
413 de Haydu C, Black JD, Schwab CL, English DP, Santin AD. An update on the current pharmacotherapy for endometrial cancer. Expert Opinion on Pharmacotherapy 2015;17:489-99. [DOI: 10.1517/14656566.2016.1127351] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
414 Barrett D, Brown VI, Grupp SA, Teachey DT. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs 2012;14:299-316. [PMID: 22845486 DOI: 10.2165/11594740-000000000-00000] [Cited by in Crossref: 16] [Cited by in F6Publishing: 44] [Article Influence: 1.8] [Reference Citation Analysis]
415 Prestwich GD, Chen R, Feng L, Ozaki S, Ferguson CG, Drees BE, Neklason DA, Mostert MJ, Porter-gill PA, Kang VH, Shope JC, Neilsen PO, Dewald DB. In situ detection of phospholipid and phosphoinositide metabolism. Advances in Enzyme Regulation 2002;42:19-38. [DOI: 10.1016/s0065-2571(01)00039-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
416 Mendes RD, Canté-Barrett K, Pieters R, Meijerink JP. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia. Haematologica 2016;101:1010-7. [PMID: 27582570 DOI: 10.3324/haematol.2016.146381] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
417 Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. Clin Chest Med. 2011;32:703-740. [PMID: 22054881 DOI: 10.1016/j.ccm.2011.08.003] [Cited by in Crossref: 126] [Cited by in F6Publishing: 112] [Article Influence: 11.5] [Reference Citation Analysis]
418 Hu L, Jiang GY, Wang YP, Hu ZB, Zhou BY, Zhang L, Song NN, Huang Y, Chai GD, Chen JY, Lang B, Xu L, Liu JL, Li Y, Wang QX, Ding YQ. The role of PTEN in primary sensory neurons in processing itch and thermal information in mice. Cell Rep 2022;39:110724. [PMID: 35443189 DOI: 10.1016/j.celrep.2022.110724] [Reference Citation Analysis]
419 Lizardi PM, Forloni M, Wajapeyee N. Genome-wide approaches for cancer gene discovery. Trends Biotechnol 2011;29:558-68. [PMID: 21757246 DOI: 10.1016/j.tibtech.2011.06.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
420 Reiss K, Wang JY, Romano G, Furnari FB, Cavenee WK, Morrione A, Tu X, Baserga R. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene 2000;19:2687-94. [PMID: 10851068 DOI: 10.1038/sj.onc.1203587] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 2.3] [Reference Citation Analysis]
421 Yi X, Wang Z, Xiong X, Zheng X, Peng G, Xu H, Wei Q, Li H, Zhu Y, Ai J. Preparation and characterization of a polyclonal antibody against PTEN-Long. Biotechnol Appl Biochem 2021. [PMID: 34338347 DOI: 10.1002/bab.2232] [Reference Citation Analysis]
422 Ding H, Nagy A, Gutmann DH, Guha A. A review of astrocytoma models. FOC 2000;8:1-8. [DOI: 10.3171/foc.2000.8.4.2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
423 Chen CY, Chen J, He L, Stiles BL. PTEN: Tumor Suppressor and Metabolic Regulator. Front Endocrinol (Lausanne) 2018;9:338. [PMID: 30038596 DOI: 10.3389/fendo.2018.00338] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 27.3] [Reference Citation Analysis]
424 Rai P, Deenadayal M, Shivaji S. Absence of activating somatic mutations of PI3KCA and AKT1 genes in South Indian women with endometriosis. Eur J Obstet Gynecol Reprod Biol 2010;152:78-82. [PMID: 20493625 DOI: 10.1016/j.ejogrb.2010.04.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
425 Callahan R. The Role of Tumor Suppressor Genes in Breast Cancer Progression. In: Manni A, editor. Endocrinology of Breast Cancer. Totowa: Humana Press; 1999. pp. 119-32. [DOI: 10.1007/978-1-59259-699-7_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
426 He Y, Wu Y, Mishra A, Acha V, Andrews T, Hornsby PJ. Biosensor technology in aging research and age-related diseases. Ageing Res Rev 2012;11:1-9. [PMID: 22115588 DOI: 10.1016/j.arr.2011.11.004] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
427 B. Jenkins R, Curran W, B. Scott C, Cairncross G. Pilot Evaluation of 1p and 19q Deletions in Anaplastic Oligodendrogliomas Collected by a National Cooperative Cancer Treatment Group: . American Journal of Clinical Oncology 2001;24:506-8. [DOI: 10.1097/00000421-200110000-00018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
428 Feng Z, Chen J, Yang Z, Lu G, Cai Z. Expression of PTTG1 and PTEN in endometrial carcinoma: correlation with tumorigenesis and progression. Med Oncol 2012;29:304-10. [DOI: 10.1007/s12032-010-9775-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
429 Luongo F, Colonna F, Calapà F, Vitale S, Fiori ME, De Maria R. PTEN Tumor-Suppressor: The Dam of Stemness in Cancer. Cancers (Basel) 2019;11:E1076. [PMID: 31366089 DOI: 10.3390/cancers11081076] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 14.7] [Reference Citation Analysis]
430 Li Y, Yan X, Shi J, He Y, Xu J, Lin L, Chen W, Lin X, Lin X. Aberrantly expressed miR-188-5p promotes gastric cancer metastasis by activating Wnt/β-catenin signaling. BMC Cancer 2019;19:505. [PMID: 31138169 DOI: 10.1186/s12885-019-5731-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
431 Ali-osman F. Brain Tumors. In: Masters JRW, Palsson B, editors. Human Cell Culture. Dordrecht: Kluwer Academic Publishers; 2002. pp. 167-84. [DOI: 10.1007/0-306-46861-1_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
432 Chen K, Kolls JK. PTENtiating CFTR for Antimicrobial Immunity. Immunity 2017;47:1014-6. [PMID: 29262343 DOI: 10.1016/j.immuni.2017.12.002] [Reference Citation Analysis]
433 Eng C. Constipation, polyps, or cancer? letPTEN predict your future. Am J Med Genet 2003;122A:315-22. [DOI: 10.1002/ajmg.a.20477] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
434 Gomarasca M, Lombardi G, Maroni P. SUMOylation and NEDDylation in Primary and Metastatic Cancers to Bone. Front Cell Dev Biol 2022;10:889002. [DOI: 10.3389/fcell.2022.889002] [Reference Citation Analysis]
435 Ahn YT, Shin IJ, Kim JM, Kim YS, Lee C, Ju SA, An WG. Counteracting the activation of pAkt by inhibition of MEK/Erk inhibition reduces actin disruption-mediated apoptosis in PTEN-null PC3M prostate cancer cell lines. Oncol Lett 2013;6:1383-9. [PMID: 24179529 DOI: 10.3892/ol.2013.1547] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
436 Cao L, Graue-Hernandez EO, Tran V, Reid B, Pu J, Mannis MJ, Zhao M. Downregulation of PTEN at corneal wound sites accelerates wound healing through increased cell migration. Invest Ophthalmol Vis Sci 2011;52:2272-8. [PMID: 21212174 DOI: 10.1167/iovs.10-5972] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
437 Xiao WZ, Han DH, Wang F, Wang YQ, Zhu YH, Wu YF, Liu NT, Sun JY. Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis. Tumour Biol 2014;35:6687-93. [PMID: 24705863 DOI: 10.1007/s13277-014-1885-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
438 Takada H, Imoto I, Tsuda H, Sonoda I, Ichikura T, Mochizuki H, Okanoue T, Inazawa J. Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci 2005;96:100-10. [PMID: 15723654 DOI: 10.1111/j.1349-7006.2005.00016.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 3.9] [Reference Citation Analysis]
439 Adachi T, Hanaka S, Masuda T, Yoshihara H, Nagase H, Ohta K. Transduction of Phosphatase and Tensin Homolog Deleted on Chromosome 10 into Eosinophils Attenuates Survival, Chemotaxis, and Airway Inflammation. J Immunol 2007;179:8105-11. [DOI: 10.4049/jimmunol.179.12.8105] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
440 Tesio M, Trinquand A, Macintyre E, Asnafi V. Oncogenic PTEN functions and models in T-cell malignancies. Oncogene 2016;35:3887-96. [PMID: 26616857 DOI: 10.1038/onc.2015.462] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
441 Abdullah JM, Zainuddin N, Sulong S, Jaafar H, Isa MN. Molecular genetic analysis of phosphatase and tensin homolog and p16 tumor suppressor genes in patients with malignant glioma. FOC 2003;14:1-7. [DOI: 10.3171/foc.2003.14.4.6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
442 Nakonechnaya AO, Jefferson HS, Chen X, Shewchuk BM. Differential effects of exogenous and autocrine growth hormone on LNCaP prostate cancer cell proliferation and survival. J Cell Biochem 2013;114:1322-35. [DOI: 10.1002/jcb.24473] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
443 Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 1997;94:14719-24. [PMID: 9405679 DOI: 10.1073/pnas.94.26.14719] [Cited by in Crossref: 285] [Cited by in F6Publishing: 249] [Article Influence: 11.9] [Reference Citation Analysis]
444 Worley MJ, Welch WR, Berkowitz RS, Ng SW. Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013;14:5367-5379. [PMID: 23466883 DOI: 10.3390/ijms14035367] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 9.8] [Reference Citation Analysis]
445 Pomerantz JH, Blau HM. Tumor suppressors: enhancers or suppressors of regeneration? Development 2013;140:2502-12. [PMID: 23715544 DOI: 10.1242/dev.084210] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
446 Kwak MK, Johnson DT, Zhu C, Lee SH, Ye DW, Luong R, Sun Z. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors. PLoS One 2013;8:e53476. [PMID: 23308230 DOI: 10.1371/journal.pone.0053476] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
447 Poluri RTK, Audet-Walsh É. Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss? Front Oncol 2018;8:246. [PMID: 30009155 DOI: 10.3389/fonc.2018.00246] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
448 Kurose K, Araki T, Matsunaka T, Takada Y, Emi M. Variant manifestation of Cowden disease in Japan: hamartomatous polyposis of the digestive tract with mutation of the PTEN gene. Am J Hum Genet 1999;64:308-10. [PMID: 9915974 DOI: 10.1086/302207] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 0.8] [Reference Citation Analysis]
449 Zeng LF, Zhang RY, Yu ZH, Li S, Wu L, Gunawan AM, Lane BS, Mali RS, Li X, Chan RJ, Kapur R, Wells CD, Zhang ZY. Therapeutic potential of targeting the oncogenic SHP2 phosphatase. J Med Chem 2014;57:6594-609. [PMID: 25003231 DOI: 10.1021/jm5006176] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 8.1] [Reference Citation Analysis]
450 Mayr C, Beyreis M, Wagner A, Pichler M, Neureiter D, Kiesslich T. Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers. Biomed Res Int. 2016;2016:4805270. [PMID: 27957497 DOI: 10.1155/2016/4805270] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
451 Fong KM, Minna JD. Molecular biology of lung cancer: clinical implications. Clin Chest Med. 2002;23:83-101. [PMID: 11901922 DOI: 10.1016/s0272-5231(03)00062-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
452 Steinbach N, Hasson D, Mathur D, Stratikopoulos EE, Sachidanandam R, Bernstein E, Parsons RE. PTEN interacts with the transcription machinery on chromatin and regulates RNA polymerase II-mediated transcription. Nucleic Acids Res 2019;47:5573-86. [PMID: 31169889 DOI: 10.1093/nar/gkz272] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
453 Zhao L, Li R, Qiu JZ, Yu JB, Cao Y, Yuan RT. YY1-mediated PTEN dephosphorylation antagonizes IR-induced DNA repair contributing to tongue squamous cell carcinoma radiosensitization. Mol Cell Probes 2020;53:101577. [PMID: 32334006 DOI: 10.1016/j.mcp.2020.101577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
454 Heinrich F, Chakravarthy S, Nanda H, Papa A, Pandolfi PP, Ross AH, Harishchandra RK, Gericke A, Lösche M. The PTEN Tumor Suppressor Forms Homodimers in Solution. Structure 2015;23:1952-7. [PMID: 26299948 DOI: 10.1016/j.str.2015.07.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
455 López-Caamal F, García MR, Middleton RH, Huber HJ. Positive feedback in the Akt/mTOR pathway and its implications for growth signal progression in skeletal muscle cells: an analytical study. J Theor Biol 2012;301:15-27. [PMID: 22314407 DOI: 10.1016/j.jtbi.2012.01.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
456 Guo YY, Wei MX. Effect of Huatan Xiaoyu Fang on expression of Notch1, β-catenin and PTEN in precancerous lesions of gastric cancer in rats. Shijie Huaren Xiaohua Zazhi 2015; 23(2): 249-255 [DOI: 10.11569/wcjd.v23.i2.249] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
457 Misra S, Ghosh G, Chowdhury SG, Karmakar P. Non-canonical function of nuclear PTEN and its implication on tumorigenesis. DNA Repair (Amst) 2021;107:103197. [PMID: 34359000 DOI: 10.1016/j.dnarep.2021.103197] [Reference Citation Analysis]
458 Hobiger K, Utesch T, Mroginski MA, Seebohm G, Friedrich T. The linker pivot in Ci-VSP: the key to unlock catalysis. PLoS One 2013;8:e70272. [PMID: 23922964 DOI: 10.1371/journal.pone.0070272] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
459 Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler PH, Bose S. PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 2004;112:407-10. [PMID: 15382065 DOI: 10.1002/ijc.20447] [Cited by in Crossref: 88] [Cited by in F6Publishing: 86] [Article Influence: 4.9] [Reference Citation Analysis]
460 DiLiberti JH. Inherited macrocephaly-hamartoma syndromes. Am J Med Genet 1998;79:284-90. [PMID: 9781909 DOI: 10.1002/(sici)1096-8628(19981002)79:4<284::aid-ajmg10>3.0.co;2-n] [Cited by in Crossref: 37] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
461 Su T, Chang J, Perng L, Chang C, Wei H, Wang NM, Tsai C. Mutation Analysis of the Putative Tumor Suppressor Gene PTEN/MMAC1 in Cervical Cancer. Gynecologic Oncology 2000;76:193-9. [DOI: 10.1006/gyno.1999.5659] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
462 Barthel A, Ostrakhovitch EA, Walter PL, Kampkötter A, Klotz LO. Stimulation of phosphoinositide 3-kinase/Akt signaling by copper and zinc ions: mechanisms and consequences. Arch Biochem Biophys 2007;463:175-82. [PMID: 17509519 DOI: 10.1016/j.abb.2007.04.015] [Cited by in Crossref: 95] [Cited by in F6Publishing: 86] [Article Influence: 6.3] [Reference Citation Analysis]
463 Lin C, Liu A, Zhu J, Zhang X, Wu G, Ren P, Wu J, Li M, Li J, Song L. miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma. Nat Commun 2014;5:4620. [PMID: 25099196 DOI: 10.1038/ncomms5620] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
464 Song P, Xie Z, Wu Y, Xu J, Dong Y, Zou MH. Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. J Biol Chem 2008;283:12446-55. [PMID: 18321849 DOI: 10.1074/jbc.M708208200] [Cited by in Crossref: 56] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
465 Deloukas P, Earthrowl ME, Grafham DV, Rubenfield M, French L, Steward CA, Sims SK, Jones MC, Searle S, Scott C, Howe K, Hunt SE, Andrews TD, Gilbert JGR, Swarbreck D, Ashurst JL, Taylor A, Battles J, Bird CP, Ainscough R, Almeida JP, Ashwell RIS, Ambrose KD, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Bates K, Beasley H, Bray-allen S, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Cahill P, Camire D, Carter NP, Chapman JC, Clark SY, Clarke G, Clee CM, Clegg S, Corby N, Coulson A, Dhami P, Dutta I, Dunn M, Faulkner L, Frankish A, Frankland JA, Garner P, Garnett J, Gribble S, Griffiths C, Grocock R, Gustafson E, Hammond S, Harley JL, Hart E, Heath PD, Ho TP, Hopkins B, Horne J, Howden PJ, Huckle E, Hynds C, Johnson C, Johnson D, Kana A, Kay M, Kimberley AM, Kershaw JK, Kokkinaki M, Laird GK, Lawlor S, Lee HM, Leongamornlert DA, Laird G, Lloyd C, Lloyd DM, Loveland J, Lovell J, Mclaren S, Mclay KE, Mcmurray A, Mashreghi-mohammadi M, Matthews L, Milne S, Nickerson T, Nguyen M, Overton-larty E, Palmer SA, Pearce AV, Peck AI, Pelan S, Phillimore B, Porter K, Rice CM, Rogosin A, Ross MT, Sarafidou T, Sehra HK, Shownkeen R, Skuce CD, Smith M, Standring L, Sycamore N, Tester J, Thorpe A, Torcasso W, Tracey A, Tromans A, Tsolas J, Wall M, Walsh J, Wang H, Weinstock K, West AP, Willey DL, Whitehead SL, Wilming L, Wray PW, Young L, Chen Y, Lovering RC, Moschonas NK, Siebert R, Fechtel K, Bentley D, Durbin R, Hubbard T, Doucette-stamm L, Beck S, Smith DR, Rogers J. The DNA sequence and comparative analysis of human chromosome 10. Nature 2004;429:375-81. [DOI: 10.1038/nature02462] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
466 Zhu X, Qin X, Fei M, Hou W, Greshock J, Bachman KE, Kang J, Qin CY. Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma. Exp Ther Med 2013;5:57-64. [PMID: 23251242 DOI: 10.3892/etm.2012.749] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
467 Chan JYH, Chan SHH. Differential impacts of brain stem oxidative stress and nitrosative stress on sympathetic vasomotor tone. Pharmacol Ther 2019;201:120-36. [PMID: 31153955 DOI: 10.1016/j.pharmthera.2019.05.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
468 Bridges D, Saltiel AR. Phosphoinositides in insulin action and diabetes. Curr Top Microbiol Immunol 2012;362:61-85. [PMID: 23086413 DOI: 10.1007/978-94-007-5025-8_3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
469 Marignol L, Coffey M, Lawler M, Hollywood D. Hypoxia in prostate cancer: A powerful shield against tumour destruction? Cancer Treatment Reviews 2008;34:313-27. [DOI: 10.1016/j.ctrv.2008.01.006] [Cited by in Crossref: 87] [Cited by in F6Publishing: 85] [Article Influence: 6.2] [Reference Citation Analysis]
470 White MF, Copps KD, Ozcan U, Tseng Y. The Mechanisms of Insulin Action. Endocrinology. Elsevier; 2010. pp. 636-59. [DOI: 10.1016/b978-1-4160-5583-9.00034-4] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
471 Smith A, Ashworth A. Cancer predisposition: where's the phosphate? Curr Biol 1998;8:R241-3. [PMID: 9545192 DOI: 10.1016/s0960-9822(98)70150-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
472 Piekarski JH, Biernat W. Clinical significance of CK5/6 and PTEN protein expression in patients with bilateral breast carcinoma. Histopathology 2006;49:248-55. [PMID: 16918971 DOI: 10.1111/j.1365-2559.2006.02482.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
473 Tachibana I, Smith JS, Sato K, Hosek SM, Kimmel DW, Jenkins RB. Investigation of germline PTEN, p53, p16INK4A/p14ARF, and CDK4 alterations in familial glioma. Am J Med Genet 2000;92:136-41. [DOI: 10.1002/(sici)1096-8628(20000515)92:2<136::aid-ajmg11>3.0.co;2-s] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
474 Kim JW, Kang KH, Burrola P, Mak TW, Lemke G. Retinal degeneration triggered by inactivation of PTEN in the retinal pigment epithelium. Genes Dev 2008;22:3147-57. [PMID: 18997061 DOI: 10.1101/gad.1700108] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 3.6] [Reference Citation Analysis]
475 Wyatt LA, Filbin MT, Keirstead HS. PTEN inhibition enhances neurite outgrowth in human embryonic stem cell-derived neuronal progenitor cells. J Comp Neurol 2014;522:2741-55. [PMID: 24610700 DOI: 10.1002/cne.23580] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
476 Hedayat A, Yan S, Tsongalis G. Molecular Pathology and Testing in Melanocytic Tumors. Diagnostic Molecular Pathology. Elsevier; 2017. pp. 321-37. [DOI: 10.1016/b978-0-12-800886-7.00025-x] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
477 Fink LS, Beatty A, Devarajan K, Peri S, Peterson JR. Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes. Mol Cancer Ther 2015;14:298-306. [PMID: 25344583 DOI: 10.1158/1535-7163.MCT-14-0529] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
478 Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet. 2003;34:369-376. [PMID: 12923544 DOI: 10.1038/ng1215] [Cited by in Crossref: 505] [Cited by in F6Publishing: 447] [Article Influence: 26.6] [Reference Citation Analysis]
479 Castillo-martin M, Thin TH, Lorduy AC, Cordon-cardo C. Immunopathologic Assessment of PTEN Expression. In: Salmena L, Stambolic V, editors. PTEN. New York: Springer; 2016. pp. 23-37. [DOI: 10.1007/978-1-4939-3299-3_3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
480 Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2014;142:164-175. [PMID: 24333502 DOI: 10.1016/j.pharmthera.2013.12.004] [Cited by in Crossref: 416] [Cited by in F6Publishing: 414] [Article Influence: 46.2] [Reference Citation Analysis]
481 Subramanian A, Sharma A, Mokbel K. Insulin-like growth factor binding proteins and breast cancer. Breast Cancer Res Treat 2008;107:181-94. [DOI: 10.1007/s10549-007-9549-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
482 Pestana ES, Tenev T, Groß S, Stoyanov B, Ogata M, Böhmer F. The transmembrane protein tyrosine phosphatase RPTPσ modulates signaling of the epidermal growth factor receptor in A431 cells. Oncogene 1999;18:4069-79. [DOI: 10.1038/sj.onc.1202794] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 2.6] [Reference Citation Analysis]
483 Kale A, Aldahish A, Shah G. Calcitonin receptor is required for T-antigen-induced prostate carcinogenesis. Oncotarget 2020;11:858-74. [PMID: 32180899 DOI: 10.18632/oncotarget.27495] [Reference Citation Analysis]
484 Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11. [PMID: 9858526 DOI: 10.1128/MCB.19.1.1] [Cited by in Crossref: 1069] [Cited by in F6Publishing: 508] [Article Influence: 46.5] [Reference Citation Analysis]
485 Greener T, Zhao X, Nojima H, Eisenberg E, Greene LE. Role of Cyclin G-associated Kinase in Uncoating Clathrin-coated Vesicles from Non-neuronal Cells. Journal of Biological Chemistry 2000;275:1365-70. [DOI: 10.1074/jbc.275.2.1365] [Cited by in Crossref: 119] [Cited by in F6Publishing: 115] [Article Influence: 5.4] [Reference Citation Analysis]
486 Foley KP, Eisenman RN. Two MAD tails: what the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network. Biochim Biophys Acta 1999;1423:M37-47. [PMID: 10382539 DOI: 10.1016/s0304-419x(99)00012-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 0.3] [Reference Citation Analysis]
487 Nagai H, Kinoshita T, Suzuki H, Hatano S, Murate T, Saito H. Identification and mapping of novel tumor suppressor loci on 6p in diffuse large B-cell non-Hodgkin's lymphoma. Genes Chromosom Cancer 1999;25:277-83. [DOI: 10.1002/(sici)1098-2264(199907)25:3<277::aid-gcc10>3.0.co;2-l] [Cited by in Crossref: 15] [Article Influence: 0.7] [Reference Citation Analysis]
488 Zhang L, Yu J, Pan H, Hu P, Hao Y, Cai W, Zhu H, Yu AD, Xie X, Ma D, Yuan J. Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc Natl Acad Sci U S A 2007;104:19023-8. [PMID: 18024584 DOI: 10.1073/pnas.0709695104] [Cited by in Crossref: 346] [Cited by in F6Publishing: 328] [Article Influence: 23.1] [Reference Citation Analysis]
489 Chetram MA, Hinton CV. PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res 2012;32:190-5. [PMID: 22737980 DOI: 10.3109/10799893.2012.695798] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 6.6] [Reference Citation Analysis]
490 Martin SK, Fiandalo MV, Kyprianou N. Androgen Receptor Signaling Interactions Control Epithelial–Mesenchymal Transition (EMT) in Prostate Cancer Progression. In: Wang Z, editor. Androgen-Responsive Genes in Prostate Cancer. New York: Springer; 2013. pp. 227-55. [DOI: 10.1007/978-1-4614-6182-1_15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
491 Zhang H, Wang Y, Xie JF, Liang X, Liu D, Yang P, Hsu H, Ray RB, Mountz JD. Regulation of tumor necrosis factor ?-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis & Rheumatism 2001;44:1555-67. [DOI: 10.1002/1529-0131(200107)44:7<1555::aid-art279>3.0.co;2-m] [Cited by in Crossref: 83] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
492 Fang LY, Izumi K, Lai KP, Liang L, Li L, Miyamoto H, Lin WJ, Chang C. Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling. Cancer Res. 2013;73:5633-5646. [PMID: 23878190 DOI: 10.1158/0008-5472.can-12-3228] [Cited by in Crossref: 83] [Cited by in F6Publishing: 60] [Article Influence: 9.2] [Reference Citation Analysis]
493 Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK, Eng C. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer. 2002;99:63-67. [PMID: 11948493 DOI: 10.1002/ijc.10294] [Cited by in Crossref: 121] [Cited by in F6Publishing: 120] [Article Influence: 6.1] [Reference Citation Analysis]
494 Li PE, Nelson PS. Prostate cancer genomics. Curr Urol Rep 2001;2:70-8. [PMID: 12084298 DOI: 10.1007/s11934-001-0028-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
495 Choo EF, Ng CM, Berry L, Belvin M, Lewin-Koh N, Merchant M, Salphati L. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. Cancer Chemother Pharmacol 2013;71:133-43. [PMID: 23053270 DOI: 10.1007/s00280-012-1988-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
496 Atif F, Yousuf S, Stein DG. Anti-tumor effects of progesterone in human glioblastoma multiforme: role of PI3K/Akt/mTOR signaling. J Steroid Biochem Mol Biol 2015;146:62-73. [PMID: 24787660 DOI: 10.1016/j.jsbmb.2014.04.007] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 6.6] [Reference Citation Analysis]
497 Zhu Y, Tang H, Zhang L, Gong L, Wu G, Ni J, Tang X. Suppression of miR-21-3p enhances TRAIL-mediated apoptosis in liver cancer stem cells by suppressing the PI3K/Akt/Bad cascade via regulating PTEN. Cancer Manag Res 2019;11:955-68. [PMID: 30774424 DOI: 10.2147/CMAR.S183328] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
498 Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001;159:359-67. [PMID: 11438483 DOI: 10.1016/S0002-9440(10)61702-6] [Cited by in Crossref: 111] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
499 Pardhi TR, Patel MS, Sudarsanam V, Vasu KK. Design, synthesis, and evaluation of 4,5,6,7-tetrahydrobenzo[d]thiazole-based novel dual kinase inhibitors of CK2 and GSK3β. Medchemcomm 2018;9:1472-90. [PMID: 30288222 DOI: 10.1039/c8md00321a] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
500 Poli A, Fiume R, Mongiorgi S, Zaurito A, Sheth B, Vidalle MC, Hamid SA, Kimber S, Campagnoli F, Ratti S, Rusciano I, Faenza I, Manzoli L, Divecha N. Exploring the controversial role of PI3K signalling in CD4+ regulatory T (T-Reg) cells. Adv Biol Regul 2020;76:100722. [PMID: 32362560 DOI: 10.1016/j.jbior.2020.100722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
501 Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, Bigner DD. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opinion on Investigational Drugs 2009;18:1061-83. [DOI: 10.1517/13543780903052764] [Cited by in Crossref: 316] [Cited by in F6Publishing: 304] [Article Influence: 24.3] [Reference Citation Analysis]
502 Nothnick WB, Peterson R, Minchella P, Falcone T, Graham A, Findley A. The Relationship and Expression of miR-451a, miR-25-3p and PTEN in Early Peritoneal Endometriotic Lesions and Their Modulation In Vitro. Int J Mol Sci 2022;23:5862. [PMID: 35682544 DOI: 10.3390/ijms23115862] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
503 Walker CJ, Goodfellow PJ. Traditional Approaches to Molecular Genetic Analysis. In: Hedrick Ellenson L, editor. Molecular Genetics of Endometrial Carcinoma. Cham: Springer International Publishing; 2017. pp. 99-118. [DOI: 10.1007/978-3-319-43139-0_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
504 Johansson Swartling F. Identifying candidate genes involved in brain tumor formation. Ups J Med Sci 2008;113:1-38. [PMID: 18521796 DOI: 10.3109/2000-1967-215] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
505 Wu Y, Niu D, Deng S, Lei X, Xie Z, Yang X. Tumor-derived or non-tumor-derived exosomal noncodingRNAs and signaling pathways in tumor microenvironment. International Immunopharmacology 2022;106:108626. [DOI: 10.1016/j.intimp.2022.108626] [Reference Citation Analysis]
506 Grapsa D, Frangou-plemenou M, Kondi-pafiti A, Stergiou E, Nicolopoulou-stamati P, Patsouris E, Chelidonis G, Athanassiadou P. “Immunocytochemical expression of P53, PTEN, FAS (CD95), P16INK4A and HPV L1 major capsid proteins in ThinPrep cervical samples with squamous intraepithelial lesions”: Apoptosis Markers in Cervical Lesions. Diagn Cytopathol 2014;42:465-75. [DOI: 10.1002/dc.23003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
507 Luo S, Lei K, Xiang D, Ye K. NQO1 Is Regulated by PTEN in Glioblastoma, Mediating Cell Proliferation and Oxidative Stress. Oxid Med Cell Longev 2018;2018:9146528. [PMID: 30595797 DOI: 10.1155/2018/9146528] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
508 Elo JP, Visakorpi T. Molecular genetics of prostate cancer. Annals of Medicine 2009;33:130-41. [DOI: 10.3109/07853890109002068] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
509 Brognard J, Hunter T. Protein kinase signaling networks in cancer. Curr Opin Genet Dev 2011;21:4-11. [PMID: 21123047 DOI: 10.1016/j.gde.2010.10.012] [Cited by in Crossref: 157] [Cited by in F6Publishing: 129] [Article Influence: 13.1] [Reference Citation Analysis]
510 Lee K, Park J, Lee S, Lim H, Jang Y, Park H. Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity. Biochemical and Biophysical Research Communications 2006;346:83-8. [DOI: 10.1016/j.bbrc.2006.05.069] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
511 Shojaee S, Chan LN, Buchner M, Cazzaniga V, Cosgun KN, Geng H, Qiu YH, von Minden MD, Ernst T, Hochhaus A, Cazzaniga G, Melnick A, Kornblau SM, Graeber TG, Wu H, Jumaa H, Müschen M. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat Med 2016;22:379-87. [PMID: 26974310 DOI: 10.1038/nm.4062] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 10.7] [Reference Citation Analysis]
512 Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, Mccubrey JA. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008;22:686-707. [DOI: 10.1038/leu.2008.26] [Cited by in Crossref: 251] [Cited by in F6Publishing: 246] [Article Influence: 17.9] [Reference Citation Analysis]
513 Ke X, Yan R, Sun Z, Cheng Y, Meltzer A, Lu N, Shu X, Wang Z, Huang B, Liu X, Wang Z, Song JH, Ng CK, Ibrahim S, Abraham JM, Shin EJ, He S, Meltzer SJ. Esophageal Adenocarcinoma-Derived Extracellular Vesicle MicroRNAs Induce a Neoplastic Phenotype in Gastric Organoids. Neoplasia. 2017;19:941-949. [PMID: 28968550 DOI: 10.1016/j.neo.2017.06.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
514 Gong ZH, Zhou F, Shi C, Xiang T, Zhou CK, Wang QQ, Jiang YS, Gao SF. miRNA-221 promotes cutaneous squamous cell carcinoma progression by targeting PTEN. Cell Mol Biol Lett 2019;24:9. [PMID: 30891072 DOI: 10.1186/s11658-018-0131-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
515 Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schiff R, Bentires-Alj M, Elledge SJ, Westbrook TF. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 2011;144:703-18. [PMID: 21376233 DOI: 10.1016/j.cell.2011.02.003] [Cited by in Crossref: 188] [Cited by in F6Publishing: 182] [Article Influence: 17.1] [Reference Citation Analysis]
516 Park JK, Jung HY, Park SH, Kang SY, Yi MR, Um HD, Hong SH. Combination of PTEN and gamma-ionizing radiation enhances cell death and G(2)/M arrest through regulation of AKT activity and p21 induction in non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys. 2008;70:1552-1560. [PMID: 18374229 DOI: 10.1016/j.ijrobp.2007.11.069] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
517 Shen X, Zhang L, Li J, Li Y, Wang Y, Xu ZX. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Front Immunol 2019;10:1337. [PMID: 31258527 DOI: 10.3389/fimmu.2019.01337] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 16.7] [Reference Citation Analysis]
518 Cool M, Depault F, Jolicoeur P. Fine allelotyping ofErbb2-induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor-suppressor loci. Genes Chromosom Cancer 2006;45:191-202. [DOI: 10.1002/gcc.20276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
519 Lin PY, Fosmire SP, Park SH, Park JY, Baksh S, Modiano JF, Weiss RH. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol Cancer. 2007;6:16. [PMID: 17300726 DOI: 10.1186/1476-4598-6-16] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
520 Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 2020;20:25-39. [PMID: 31570880 DOI: 10.1038/s41577-019-0218-4] [Cited by in Crossref: 217] [Cited by in F6Publishing: 216] [Article Influence: 72.3] [Reference Citation Analysis]
521 Alimonti A. PTEN breast cancer susceptibility: a matter of dose. Ecancermedicalscience 2010;4:192. [PMID: 22276040 DOI: 10.3332/ecancer.2010.192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
522 Barata JT. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Adv Enzyme Regul 2011;51:37-49. [PMID: 21035501 DOI: 10.1016/j.advenzreg.2010.09.012] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
523 Lu TL, Huang YF, You LR, Chao NC, Su FY, Chang JL, Chen CM. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice. Am J Pathol 2013;182:975-91. [PMID: 23313138 DOI: 10.1016/j.ajpath.2012.11.025] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 7.4] [Reference Citation Analysis]
524 Anai S, Goodison S, Shiverick K, Iczkowski K, Tanaka M, Rosser CJ. Combination of PTEN Gene Therapy and Radiation Inhibits the Growth of Human Prostate Cancer Xenografts. Human Gene Therapy 2006;17:975-84. [DOI: 10.1089/hum.2006.17.975] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
525 Fernández S, García-García M, Torres-Alemán I. Modulation by insulin-like growth factor I of the phosphatase PTEN in astrocytes. Biochim Biophys Acta 2008;1783:803-12. [PMID: 18062928 DOI: 10.1016/j.bbamcr.2007.10.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
526 Giordano G, Pizzi S, Azzoni C, Bottarelli L, D'Adda T. Primary squamous cell carcinoma of the endometrium unrelated to human papilloma virus: a molecular study. Pathol Oncol Res 2013;19:495-9. [PMID: 23430758 DOI: 10.1007/s12253-013-9607-3] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
527 Kobayashi Y, Lim SO, Yamaguchi H. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. Semin Cancer Biol 2020;65:51-64. [PMID: 31874279 DOI: 10.1016/j.semcancer.2019.11.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
528 Barami K. Biology of the subventricular zone in relation to gliomagenesis. Journal of Clinical Neuroscience 2007;14:1143-9. [DOI: 10.1016/j.jocn.2007.04.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
529 Ren W, Zhang X, Li W, Feng Q, Feng H, Tong Y, Rong H, Wang W, Zhang D, Zhang Z, Tu S, Zhu X, Zhang Q. Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer. Cancer Manag Res 2019;11:4023-40. [PMID: 31190980 DOI: 10.2147/CMAR.S198886] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
530 Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer Res 2014;74:3180-94. [PMID: 24662921 DOI: 10.1158/0008-5472.CAN-13-3415] [Cited by in Crossref: 73] [Cited by in F6Publishing: 49] [Article Influence: 9.1] [Reference Citation Analysis]
531 Galluzzi L, Linkermann A, Kepp O, Kroemer G. Pathophysiology of Cancer Cell Death. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 74-83.e4. [DOI: 10.1016/b978-0-323-47674-4.00005-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
532 van der Poel HG. Molecular markers in the diagnosis of prostate cancer. Crit Rev Oncol Hematol 2007;61:104-39. [PMID: 16945550 DOI: 10.1016/j.critrevonc.2006.07.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
533 Gong Y, Yang H, Tian X. Elucidating the mechanism of miRNA-214 in the regulation of gingival carcinoma. Exp Ther Med 2017;13:2544-50. [PMID: 28565877 DOI: 10.3892/etm.2017.4264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
534 Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28:29-35. [PMID: 11326271 DOI: 10.1038/ng0501-29] [Cited by in Crossref: 253] [Cited by in F6Publishing: 352] [Article Influence: 12.0] [Reference Citation Analysis]
535 Park MJ, Kwak HJ, Lee HC, Yoo DH, Park IC, Kim MS, Lee SH, Rhee CH, Hong SI. Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor. J Biol Chem 2007;282:30485-96. [PMID: 17666398 DOI: 10.1074/jbc.M701081200] [Cited by in Crossref: 70] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
536 Park SR, Chen A. Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. Hematol Oncol Clin North Am 2012;26:649-70, ix. [PMID: 22520984 DOI: 10.1016/j.hoc.2012.02.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
537 Shen Z, Lin L, Cao B, Zhou C, Hao W, Ye D. LZTS2 promoter hypermethylation: a potential biomarker for the diagnosis and prognosis of laryngeal squamous cell carcinoma. World J Surg Oncol 2018;16:42. [PMID: 29499699 DOI: 10.1186/s12957-018-1349-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
538 Fujii GH, Morimoto AM, Berson AE, Bolen JB. Transcriptional analysis of the PTEN/MMAC1 pseudogene, psiPTEN. Oncogene 1999;18:1765-9. [PMID: 10208437 DOI: 10.1038/sj.onc.1202492] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 2.5] [Reference Citation Analysis]
539 Whelan JT, Kellogg A, Shewchuk BM, Hewan-Lowe K, Bertrand FE. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. J Cell Biochem 2009;107:992-1001. [PMID: 19479935 DOI: 10.1002/jcb.22199] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
540 White RL. Tumor suppressing pathways. Cell. 1998;92:591-592. [PMID: 9506511 DOI: 10.1016/s0092-8674(00)81124-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
541 Kaur G, Balasubramaniam SD, Lee YJ. IGFBP-2 in cervical cancer development. Exp Mol Pathol 2020;113:104362. [PMID: 31870856 DOI: 10.1016/j.yexmp.2019.104362] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
542 Lee SH, Lee YP, Kim SY, Jeong MS, Lee MJ, Kang HW, Jeong HJ, Kim DW, Sohn EJ, Jang SH, Kim YH, Kwon HJ, Cho SW, Park J, Eum WS, Choi SY. Inhibition of LPS-induced cyclooxygenase 2 and nitric oxide production by transduced PEP-1-PTEN fusion protein in Raw 264.7 macrophage cells. Exp Mol Med 2008;40:629-38. [PMID: 19116448 DOI: 10.3858/emm.2008.40.6.629] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
543 Srikantan V, Srivastava S. Molecular Dissection of the Prostate Cancer Genome. In: Hofmann R, Heidenreich A, Moul JW, editors. Prostate Cancer. Berlin: Springer Berlin Heidelberg; 2003. pp. 25-40. [DOI: 10.1007/978-3-642-56321-8_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
544 Peng H, Chen Y, Gong P, Cai L, Lyu X, Jiang Q, Wang J, Lu J, Yao K, Liu K, Li J, Li X. Higher methylation intensity induced by EBV LMP1 via NF-κB/DNMT3b signaling contributes to silencing of PTEN gene. Oncotarget 2016;7:40025-37. [PMID: 27223069 DOI: 10.18632/oncotarget.9474] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
545 Wezel F, Lustig J, Azoitei A, Liu J, Meessen S, Najjar G, Zehe V, Faustmann P, Zengerling F, John A, Martini T, Bolenz C, Günes C. Grainyhead-Like 3 Influences Migration and Invasion of Urothelial Carcinoma Cells. Int J Mol Sci 2021;22:2959. [PMID: 33803949 DOI: 10.3390/ijms22062959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
546 Varella-Garcia M. Chromosomal and genomic changes in lung cancer. Cell Adh Migr 2010;4:100-6. [PMID: 20139701 DOI: 10.4161/cam.4.1.10884] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
547 Hlobilková A, Knillová J, Bártek J, Lukás J, Kolár Z. The mechanism of action of the tumour suppressor gene PTEN. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2003;147:19-25. [PMID: 15034601 DOI: 10.5507/bp.2003.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
548 Olschwang S, Markie D, Seal S, Neale K, Phillips R, Cottrell S, Ellis I, Hodgson S, Zauber P, Spigelman A. Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3. J Med Genet. 1998;35:42-44. [PMID: 9475093 DOI: 10.1136/jmg.35.1.42] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 2.5] [Reference Citation Analysis]
549 Li C, Li H. Network-constrained regularization and variable selection for analysis of genomic data. Bioinformatics. 2008;24:1175-1182. [PMID: 18310618 DOI: 10.1093/bioinformatics/btn081] [Cited by in Crossref: 347] [Cited by in F6Publishing: 222] [Article Influence: 24.8] [Reference Citation Analysis]
550 Zhang J, Li X, Zhang Y. Correlation of NEDD4-1 and PTEN expression with the invasive capacity of pituitary adenomas. Mol Clin Oncol 2017;6:96-100. [PMID: 28123738 DOI: 10.3892/mco.2016.1092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
551 Baldinu P, Cossu A, Manca A, Satta MP, Pisano M, Casula M, Dessole S, Pintus A, Tanda F, Palmieri G. Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma. Cancer 2002;94:3157-68. [DOI: 10.1002/cncr.10606] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
552 Feng DD, Cai W, Chen X. The associations between Parkinson's disease and cancer: the plot thickens. Transl Neurodegener 2015;4:20. [PMID: 26504519 DOI: 10.1186/s40035-015-0043-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
553 Li L, Ross AH. Why is PTEN an important tumor suppressor? J Cell Biochem 2007;102:1368-74. [DOI: 10.1002/jcb.21593] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 4.9] [Reference Citation Analysis]
554 Vanharanta S, Wortham NC, Laiho P, Sjöberg J, Aittomäki K, Arola J, Tomlinson IP, Karhu A, Arango D, Aaltonen LA. 7q deletion mapping and expression profiling in uterine fibroids. Oncogene 2005;24:6545-54. [DOI: 10.1038/sj.onc.1208784] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
555 Mehmood S, Faheem M, Ismail H, Farhat SM, Ali M, Younis S, Asghar MN. ‘Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics’. Front Mol Biosci 2022;9:783494. [DOI: 10.3389/fmolb.2022.783494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
556 Qin YM, Han Y, Zhang CX, Chang TM. Correlation of PTEN expression with microvessel density and pathological parameters in esophageal carcinoma. Shijie Huaren Xiaohua Zazhi 2009; 17(29): 3023-3027 [DOI: 10.11569/wcjd.v17.i29.3023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
557 Lieberman-Cribbin W, Tuminello S, Gillezeau C, van Gerwen M, Brody R, Mulholland DJ, Horton L, Sisco M, Prophete C, Zelikoff J, Lee HW, Park SH, Chen LC, Cohen MD, Taioli E. Complementary biobank of rodent tissue samples to study the effect of World Trade Center exposure on cancer development. J Transl Med 2019;17:342. [PMID: 31601237 DOI: 10.1186/s12967-019-2089-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
558 Brognard J, Niederst M, Reyes G, Warfel N, Newton AC. Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C. J Biol Chem 2009;284:15215-23. [PMID: 19324870 DOI: 10.1074/jbc.M901468200] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
559 Agrawal S, Pilarski R, Eng C. Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN. Human Molecular Genetics 2005;14:2459-68. [DOI: 10.1093/hmg/ddi246] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
560 Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346-352. [PMID: 22522925 DOI: 10.1038/nature10983.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
561 Anderson MW, Moss JJ, Szalai R, Lane JD. Mathematical Modeling Highlights the Complex Role of AKT in TRAIL-Induced Apoptosis of Colorectal Carcinoma Cells. iScience 2019;12:182-93. [PMID: 30690394 DOI: 10.1016/j.isci.2019.01.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
562 Cai Y, Wang J, Li R, Ayala G, Ittmann M, Liu M. GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression. Cancer Res 2009;69:819-27. [PMID: 19176382 DOI: 10.1158/0008-5472.CAN-08-2537] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
563 Kwon CH, Zhu X, Zhang J, Knoop LL, Tharp R, Smeyne RJ, Eberhart CG, Burger PC, Baker SJ. Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet 2001;29:404-11. [PMID: 11726927 DOI: 10.1038/ng781] [Cited by in Crossref: 314] [Cited by in F6Publishing: 313] [Article Influence: 15.0] [Reference Citation Analysis]
564 Narla G, Sangodkar J, Ryder CB. The impact of phosphatases on proliferative and survival signaling in cancer. Cell Mol Life Sci 2018;75:2695-718. [PMID: 29725697 DOI: 10.1007/s00018-018-2826-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
565 Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist. 2011;16:404-414. [PMID: 21406469 DOI: 10.1634/theoncologist.2010-0402] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 9.8] [Reference Citation Analysis]
566 Li L, Liu F, Salmonsen RA, Turner TK, Litofsky NS, Di Cristofano A, Pandolfi PP, Jones SN, Recht LD, Ross AH. PTEN in neural precursor cells: regulation of migration, apoptosis, and proliferation. Mol Cell Neurosci 2002;20:21-9. [PMID: 12056837 DOI: 10.1006/mcne.2002.1115] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 4.7] [Reference Citation Analysis]
567 Bertoli C, Copetti T, Lam EW, Demarchi F, Schneider C. Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. Oncogene 2009;28:721-33. [PMID: 19029949 DOI: 10.1038/onc.2008.425] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
568 Wangari-Talbot J, Chen S. Genetics of melanoma. Front Genet 2012;3:330. [PMID: 23372575 DOI: 10.3389/fgene.2012.00330] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
569 Staal FJ, van der Luijt RB, Baert MR, van Drunen J, van Bakel H, Peters E, de Valk I, van Amstel HK, Taphoorn MJ, Jansen GH, van Veelen CW, Burgering B, Staal GE. A novel germline mutation of PTEN associated with brain tumours of multiple lineages. Br J Cancer 2002;86:1586-91. [PMID: 12085208 DOI: 10.1038/sj.bjc.6600206] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
570 Terracciano L, Richter J, Tornillo L, Beffa L, Diener P, Maurer R, Gasser TC, Moch H, Mihatsch MJ, Sauter G. Chromosomal imbalances in small cell carcinomas of the urinary bladder. J Pathol 1999;189:230-5. [DOI: 10.1002/(sici)1096-9896(199910)189:2<230::aid-path407>3.0.co;2-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
571 Thiery-vuillemin A, Nguyen T, Pivot X, Spano J, Dufresnne A, Soria J. Molecularly targeted agents: Their promise as cancer chemopreventive interventions. European Journal of Cancer 2005;41:2003-15. [DOI: 10.1016/j.ejca.2005.06.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
572 Jia H, Sun W, Li X, Xu W. Melatonin promotes apoptosis of thyroid cancer cells via regulating the signaling of microRNA-21 (miR-21) and microRNA-30e (miR-30e). Bioengineered 2022;13:9588-601. [PMID: 35412442 DOI: 10.1080/21655979.2022.2054206] [Reference Citation Analysis]
573 Ding X, Li F, McKnight J, Schmidt C, Strooisma K, Shimizu H, Faber K, Ware JA, Dean B. A supported liquid extraction-LC-MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma. J Pharm Biomed Anal 2014;100:150-6. [PMID: 25165011 DOI: 10.1016/j.jpba.2014.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
574 Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273:13375-13378. [PMID: 9593664 DOI: 10.1074/jbc.273.22.13375] [Cited by in Crossref: 2085] [Cited by in F6Publishing: 2030] [Article Influence: 86.9] [Reference Citation Analysis]
575 Jezek J, Wang K, Yan R, Di Cristofano A, Cooper KF, Strich R. Synergistic repression of thyroid hyperplasia by cyclin C and Pten. J Cell Sci 2019;132:jcs230029. [PMID: 31331961 DOI: 10.1242/jcs.230029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
576 Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA. 1998;95:15406-15411. [PMID: 9860981 DOI: 10.1073/pnas.95.26.15406] [Cited by in Crossref: 323] [Cited by in F6Publishing: 306] [Article Influence: 14.0] [Reference Citation Analysis]
577 Hausott B, Glueckert R, Schrott-fischer A, Klimaschewski L. Signal Transduction Regulators in Axonal Regeneration. Cells 2022;11:1537. [DOI: 10.3390/cells11091537] [Reference Citation Analysis]
578 Zhang L, Huang C, Guo Y, Gou X, Hinsdale M, Lloyd P, Liu L. MicroRNA-26b Modulates the NF-κB Pathway in Alveolar Macrophages by Regulating PTEN. J Immunol 2015;195:5404-14. [PMID: 26503952 DOI: 10.4049/jimmunol.1402933] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
579 Yuan X, Bu H, Zhou J, Yang C, Zhang H. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application. J Med Chem 2020;63:11368-96. [DOI: 10.1021/acs.jmedchem.0c00249] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 12.5] [Reference Citation Analysis]
580 Böttcher R, Kweldam CF, Livingstone J, Lalonde E, Yamaguchi TN, Huang V, Yousif F, Fraser M, Bristow RG, van der Kwast T, Boutros PC, Jenster G, van Leenders GJLH. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer 2018;18:8. [PMID: 29295717 DOI: 10.1186/s12885-017-3976-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
581 Kim JS, Peng X, De PK, Geahlen RL, Durden DL. PTEN controls immunoreceptor (immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac. Blood 2002;99:694-7. [PMID: 11781256 DOI: 10.1182/blood.v99.2.694] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
582 Kurebayashi J. Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer 2003;10:112-9. [PMID: 12736563 DOI: 10.1007/BF02967635] [Cited by in Crossref: 37] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
583 Putz U, Howitt J, Doan A, Goh CP, Low LH, Silke J, Tan SS. The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells. Sci Signal. 2012;5:ra70. [PMID: 23012657 DOI: 10.1126/scisignal.2003084] [Cited by in Crossref: 188] [Cited by in F6Publishing: 185] [Article Influence: 18.8] [Reference Citation Analysis]
584 Abbas A, Padmanabhan R, Eng C. Metabolic stress regulates genome-wide transcription in a PTEN-dependent manner. Hum Mol Genet 2020;29:2736-45. [PMID: 32744308 DOI: 10.1093/hmg/ddaa168] [Reference Citation Analysis]
585 Grzmil M, Hemmings BA. Deregulated signalling networks in human brain tumours. Biochim Biophys Acta 2010;1804:476-83. [PMID: 19879382 DOI: 10.1016/j.bbapap.2009.10.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
586 Leslie NR, Gray A, Pass I, Orchiston EA, Downes CP. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase. Biochem J. 2000;346 Pt 3:827-833. [PMID: 10698713 DOI: 10.1042/0264-6021:3460827] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
587 Yang J, Ren Y, Wang L, Li B, Chen Y, Zhao W, Xu W, Li T, Dai F. PTEN mutation spectrum in breast cancers and breast hyperplasia. J Cancer Res Clin Oncol 2010;136:1303-11. [DOI: 10.1007/s00432-010-0781-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
588 Luo J, Liu Z. Long non-coding RNA TTN-AS1 promotes the progression of lung adenocarcinoma by regulating PTEN/PI3K/AKT signaling pathway. Biochemical and Biophysical Research Communications 2019;514:140-7. [DOI: 10.1016/j.bbrc.2019.04.050] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
589 Gravina GL, Festuccia C, Marampon F, Popov VM, Pestell RG, Zani BM, Tombolini V. Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer. 2010;9:305. [PMID: 21108789 DOI: 10.1186/1476-4598-9-305] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
590 Gimm O, Gössling A, Marsh DJ, Dahia PL, Mulligan LM, von Deimling A, Eng C. Mutation and deletion analysis of GFR alpha-1, encoding the co-receptor for the GDNF/RET complex, in human brain tumours. Br J Cancer 1999;80:383-6. [PMID: 10408842 DOI: 10.1038/sj.bjc.6690367] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
591 Tsujiuchi T, Sasaki Y, Tsutsumi M, Konishi Y. Absence of PTEN/MMAC1 gene mutations in lung adenocarcinomas induced by N -nitrosobis(2-hydroxypropyl)amine in rats. Cancer Letters 2001;162:207-11. [DOI: 10.1016/s0304-3835(00)00655-8] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
592 Han S, Polizzano C, Nielsen GP, Hornicek FJ, Rosenberg AE, Ramesh V. Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res 2009;15:1940-6. [PMID: 19276265 DOI: 10.1158/1078-0432.CCR-08-2364] [Cited by in Crossref: 41] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
593 Yu X, Li S, Pang M, Du Y, Xu T, Bai T, Yang K, Hu J, Zhu S, Wang L, Liu X. TSPAN7 Exerts Anti-Tumor Effects in Bladder Cancer Through the PTEN/PI3K/AKT Pathway. Front Oncol 2020;10:613869. [PMID: 33489923 DOI: 10.3389/fonc.2020.613869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
594 Dasgupta P, Kulkarni P, Majid S, Shahryari V, Hashimoto Y, Bhat NS, Shiina M, Deng G, Saini S, Tabatabai ZL, Yamamura S, Tanaka Y, Dahiya R. MicroRNA-203 Inhibits Long Noncoding RNA HOTAIR and Regulates Tumorigenesis through Epithelial-to-mesenchymal Transition Pathway in Renal Cell Carcinoma. Mol Cancer Ther 2018;17:1061-9. [PMID: 29440295 DOI: 10.1158/1535-7163.MCT-17-0925] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 12.8] [Reference Citation Analysis]
595 Yan X, Fraser M, Qiu Q, Tsang BK. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecologic Oncology 2006;102:348-55. [DOI: 10.1016/j.ygyno.2005.12.033] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 4.4] [Reference Citation Analysis]
596 Kriplani N, Hermida MA, Brown ER, Leslie NR. Class I PI 3-kinases: Function and evolution. Advances in Biological Regulation 2015;59:53-64. [DOI: 10.1016/j.jbior.2015.05.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
597 Hamilton JA, Stewart LM, Ajayi L, Gray IC, Gray NE, Roberts KG, Watson GJ, Kaisary AV, Snary D. The expression profile for the tumour suppressor gene PTEN and associated polymorphic markers. Br J Cancer 2000;82:1671-6. [PMID: 10817502 DOI: 10.1054/bjoc.2000.1211] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
598 Ishihara H, Sasaoka T, Kagawa S, Murakami S, Fukui K, Kawagishi Y, Yamazaki K, Sato A, Iwata M, Urakaze M. Association of the polymorphisms in the 5’-untranslated region of PTEN gene with type 2 diabetes in a Japanese population. FEBS Lett. 2003;554:450-454. [PMID: 14623110 DOI: 10.1016/s0014-5793(03)01225-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
599 Giefing M, Arnemann J, Martin-Subero JI, Nieländer I, Bug S, Hartmann S, Arnold N, Tiacci E, Frank M, Hansmann ML, Küppers R, Siebert R. Identification of candidate tumour suppressor gene loci for Hodgkin and Reed-Sternberg cells by characterisation of homozygous deletions in classical Hodgkin lymphoma cell lines. Br J Haematol 2008;142:916-24. [PMID: 18671701 DOI: 10.1111/j.1365-2141.2008.07262.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
600 Chernova O, Cowell JK. Molecular Definition of Chromosome Translocations Involving 10q24 and 19q13 in Human Malignant Glioma Cells. Cancer Genetics and Cytogenetics 1998;105:60-8. [DOI: 10.1016/s0165-4608(97)00479-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
601 Taylor GS, Dixon JE. PTEN and myotubularins: families of phosphoinositide phosphatases. Methods Enzymol 2003;366:43-56. [PMID: 14674238 DOI: 10.1016/s0076-6879(03)66004-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
602 Newton HB. Overview of the Molecular Genetics and Molecular Chemotherapy of GBM. In: Ray SK, editor. Glioblastoma. New York: Springer; 2010. pp. 1-42. [DOI: 10.1007/978-1-4419-0410-2_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
603 Xi Y, Chen Y. PTEN Plays Dual Roles As a Tumor Suppressor in Osteosarcoma Cells. J Cell Biochem 2017;118:2684-92. [PMID: 28106296 DOI: 10.1002/jcb.25888] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
604 Rozanov D, Cheltsov A, Sergienko E, Vasile S, Golubkov V, Aleshin AE, Levin T, Traer E, Hann B, Freimuth J, Alexeev N, Alekseyev MA, Budko SP, Bächinger HP, Spellman P. TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response. PLoS One 2015;10:e0129566. [PMID: 26075913 DOI: 10.1371/journal.pone.0129566] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
605 Deng W, Wang Y, Long X, Zhao R, Wang Z, Liu Z, Cao S, Shi B. miR-21 Reduces Hydrogen Peroxide-Induced Apoptosis in c-kit+ Cardiac Stem Cells In Vitro through PTEN/PI3K/Akt Signaling. Oxid Med Cell Longev 2016;2016:5389181. [PMID: 27803763 DOI: 10.1155/2016/5389181] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
606 Zhuang W, Qin Z, Liang Z. The role of autophagy in sensitizing malignant glioma cells to radiation therapy. Acta Biochim Biophys Sin (Shanghai) 2009;41:341-51. [PMID: 19430698 DOI: 10.1093/abbs/gmp028] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 7.3] [Reference Citation Analysis]
607 Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chiappetta G, Fusco A, Viglietto G. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000;19:3146-55. [PMID: 10918569 DOI: 10.1038/sj.onc.1203633] [Cited by in Crossref: 103] [Cited by in F6Publishing: 97] [Article Influence: 4.7] [Reference Citation Analysis]
608 Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011;30:2547-2557. [PMID: 21278786 DOI: 10.1038/onc.2010.626] [Cited by in Crossref: 363] [Cited by in F6Publishing: 340] [Article Influence: 33.0] [Reference Citation Analysis]
609 Hu ZI, Bangiyev L, Seidman RJ, Cohen JA. Dysphagia and Neck Swelling in a Case of Undiagnosed Lhermitte-Duclos Disease and Cowden Syndrome. Case Rep Oncol Med 2015;2015:546297. [PMID: 26448889 DOI: 10.1155/2015/546297] [Reference Citation Analysis]
610 Grønbæk K, Zeuthen J, Guldberg P, Ralfkiær E, Hou-jensen K. Alterations of the MMAC1/PTEN Gene in Lymphoid Malignancies. Blood 1998;91:4388-90. [DOI: 10.1182/blood.v91.11.4388] [Cited by in Crossref: 43] [Article Influence: 1.8] [Reference Citation Analysis]
611 Mester J, Eng C. When overgrowth bumps into cancer: the PTEN-opathies. Am J Med Genet C Semin Med Genet 2013;163C:114-21. [PMID: 23613428 DOI: 10.1002/ajmg.c.31364] [Cited by in Crossref: 87] [Cited by in F6Publishing: 80] [Article Influence: 9.7] [Reference Citation Analysis]
612 Beasley KD, Toms SA. The Molecular Pathobiology of Metastasis to the Brain: A Review. Neurosurgery Clinics of North America 2011;22:7-14. [DOI: 10.1016/j.nec.2010.08.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
613 Lee EC, Tenniswood M. Programmed cell death and survival pathways in prostate cancer cells. Arch Androl 2004;50:27-32. [PMID: 14660168 DOI: 10.1080/01485010490250498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
614 Rosser CJ, Tanaka M, Pisters LL, Tanaka N, Levy LB, Hoover DC, Grossman HB, Mcdonnell TJ, Kuban DA, Meyn RE. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther 2004;11:273-9. [DOI: 10.1038/sj.cgt.7700673] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
615 Noh WC, Kim YH, Kim MS, Koh JS, Kim HA, Moon NM, Paik NS. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat 2008;110:477-83. [PMID: 17805960 DOI: 10.1007/s10549-007-9746-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 3.3] [Reference Citation Analysis]
616 Shi Y, Paluch BE, Wang X, Jiang X. PTEN at a glance. J Cell Sci. 2012;125:4687-4692. [PMID: 23223894 DOI: 10.1242/jcs.093765] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 7.3] [Reference Citation Analysis]
617 Li Z, Liu GX, Liu YL, Chen X, Huang XL, Gan HT. Effect of adenovirus-mediated PTEN gene on ulcerative colitis-associated colorectal cancer. Int J Colorectal Dis 2013;28:1107-15. [DOI: 10.1007/s00384-013-1678-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
618 Doxey BW, Kuwada SK, Burt RW. Inherited Polyposis Syndromes: Molecular Mechanisms, Clinicopathology, and Genetic Testing. Clinical Gastroenterology and Hepatology 2005;3:633-41. [DOI: 10.1016/s1542-3565(05)00370-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
619 Saikali Z, Setya H, Singh G, Persad S. Role of IGF-1/IGF-1R in regulation of invasion in DU145 prostate cancer cells. Cancer Cell Int 2008;8:10. [PMID: 18598360 DOI: 10.1186/1475-2867-8-10] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
620 Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol. 2000;32:1123-1136. [PMID: 11137452 DOI: 10.1016/s1357-2725(00)00048-0] [Cited by in Crossref: 167] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
621 Ferrarini A, Forcato C, Buson G, Tononi P, Del Monaco V, Terracciano M, Bolognesi C, Fontana F, Medoro G, Neves R, Möhlendick B, Rihawi K, Ardizzoni A, Sumanasuriya S, Flohr P, Lambros M, de Bono J, Stoecklein NH, Manaresi N. A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. PLoS One 2018;13:e0193689. [PMID: 29494651 DOI: 10.1371/journal.pone.0193689] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
622 Houlston R, Bevan S, Williams A, Young J, Dunlop M, Rozen P, Eng C, Markie D, Woodford-Richens K, Rodriguez-Bigas MA, Leggett B, Neale K, Phillips R, Sheridan E, Hodgson S, Iwama T, Eccles D, Bodmer W, Tomlinson I. Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only account for a minority of cases. Hum Mol Genet 1998;7:1907-12. [PMID: 9811934 DOI: 10.1093/hmg/7.12.1907] [Cited by in Crossref: 93] [Cited by in F6Publishing: 73] [Article Influence: 3.9] [Reference Citation Analysis]
623 Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH, Yasmeen A. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer 2017;17:638. [PMID: 28886696 DOI: 10.1186/s12885-017-3639-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
624 Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, von Deimling A, Poustka A. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet. 1997;17:32-39. [PMID: 9288095 DOI: 10.1038/ng0997-32] [Cited by in Crossref: 301] [Cited by in F6Publishing: 281] [Article Influence: 12.0] [Reference Citation Analysis]
625 Ma DZ, Xu Z, Liang YL, Su JM, Li ZX, Zhang W, Wang LY, Zha XL. Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines. World J Gastroenterol 2005; 11(29): 4472-4477 [PMID: 16052674 DOI: 10.3748/wjg.v11.i29.4472] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
626 Papa A, Caruso D, Tomao S, Rossi L, Zaccarelli E, Tomao F. Triple-negative breast cancer: investigating potential molecular therapeutic target. Expert Opin Ther Targets 2015;19:55-75. [PMID: 25307277 DOI: 10.1517/14728222.2014.970176] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
627 Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, Chibbar R. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 2005;18:250-9. [PMID: 15475931 DOI: 10.1038/modpathol.3800296] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 5.4] [Reference Citation Analysis]
628 Inoue T, Kobayashi T, Terada N, Shimizu Y, Kamoto T, Ogawa O, Nakamura E. Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells. Expert Review of Endocrinology & Metabolism 2014;2:689-704. [DOI: 10.1586/17446651.2.5.689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
629 Myers MP, Tonks NK. PTEN: sometimes taking it off can be better than putting it on. Am J Hum Genet 1997;61:1234-8. [PMID: 9399917 DOI: 10.1086/301659] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 2.3] [Reference Citation Analysis]
630 Klingler-Hoffmann M, Bukczynska P, Tiganis T. Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells. Int J Cancer 2003;105:331-9. [PMID: 12704666 DOI: 10.1002/ijc.11085] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
631 Gerry CJ, Schreiber SL. Chemical probes and drug leads from advances in synthetic planning and methodology. Nat Rev Drug Discov 2018;17:333-52. [PMID: 29651105 DOI: 10.1038/nrd.2018.53] [Cited by in Crossref: 95] [Cited by in F6Publishing: 71] [Article Influence: 23.8] [Reference Citation Analysis]
632 Pollack IF, Hamilton RL, James CD, Finkelstein SD, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL; Children's Oncology Group. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg 2006;105:418-24. [PMID: 17328268 DOI: 10.3171/ped.2006.105.5.418] [Cited by in Crossref: 25] [Cited by in F6Publishing: 70] [Article Influence: 1.7] [Reference Citation Analysis]
633 Sarris EG, Saif MW, Syrigos KN. The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals (Basel) 2012;5:1236-64. [PMID: 24281308 DOI: 10.3390/ph5111236] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
634 Feilotter HE, Coulon V, McVeigh JL, Boag AH, Dorion-Bonnet F, Duboué B, Latham WC, Eng C, Mulligan LM, Longy M. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 1999;79:718-23. [PMID: 10070859 DOI: 10.1038/sj.bjc.6690115] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 3.2] [Reference Citation Analysis]
635 Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1999;96:2110-2115. [PMID: 10051603 DOI: 10.1073/pnas.96.5.2110] [Cited by in Crossref: 410] [Cited by in F6Publishing: 404] [Article Influence: 17.8] [Reference Citation Analysis]
636 Ng HK, Lam PY. The molecular genetics of central nervous system tumors. Pathology 1998;30:196-202. [PMID: 9643506 DOI: 10.1080/00313029800169236] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
637 Wang D, Saga Y, Sato N, Nakamura T, Takikawa O, Mizukami H, Matsubara S, Fujiwara H. The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway. Int J Oncol 2016;48:2303-9. [PMID: 27082119 DOI: 10.3892/ijo.2016.3486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
638 Liang H, Chen X, Yin Q, Ruan D, Zhao X, Zhang C, McNutt MA, Yin Y. PTENβ is an alternatively translated isoform of PTEN that regulates rDNA transcription. Nat Commun 2017;8:14771. [PMID: 28332494 DOI: 10.1038/ncomms14771] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 11.6] [Reference Citation Analysis]
639 Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS Jr, Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 2000;20:1626-38. [PMID: 10669740 DOI: 10.1128/MCB.20.5.1626-1638.2000] [Cited by in Crossref: 487] [Cited by in F6Publishing: 142] [Article Influence: 22.1] [Reference Citation Analysis]
640 Fujiwara Y, Hoon DS, Yamada T, Umeshita K, Gotoh M, Sakon M, Nishisho I, Monden M. PTEN / MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas. Jpn J Cancer Res. 2000;91:287-292. [PMID: 10760687 DOI: 10.1111/j.1349-7006.2000.tb00943.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 1.3] [Reference Citation Analysis]
641 Dong XY, Rodriguez C, Guo P, Sun X, Talbot JT, Zhou W, Petros J, Li Q, Vessella RL, Kibel AS, Stevens VL, Calle EE, Dong JT. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet 2008;17:1031-42. [PMID: 18202102 DOI: 10.1093/hmg/ddm375] [Cited by in Crossref: 128] [Cited by in F6Publishing: 130] [Article Influence: 9.1] [Reference Citation Analysis]
642 Ko JY, Lee TC, Hsiao CF, Lin GL, Yen SH, Chen KY, Hsiung CA, Chen PJ, Hsu MM, Jou YS. Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT,p16(INK4A), and p19(ARF) genes in nasopharyngeal carcinoma. Cancer. 2002;94:1987-1996. [PMID: 11932901 DOI: 10.1002/cncr.10406] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
643 Seminario MC, Wange RL. Lipid phosphatases in the regulation of T cell activation: living up to their PTEN-tial. Immunol Rev 2003;192:80-97. [PMID: 12670397 DOI: 10.1034/j.1600-065x.2003.00013.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
644 Cantini LP, Meier F, Sondak VK, Smalley KS. The future of targeted therapy approaches in melanoma. Expert Opin Drug Discov 2009;4:445-56. [PMID: 23485043 DOI: 10.1517/17460440902828298] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
645 Bennett IC, Gattas M, Teh BT. The management of familial breast cancer. Breast 2000;9:247-63. [PMID: 14732174 DOI: 10.1054/brst.2000.0208] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
646 Capodanno A, Camerini A, Orlandini C, Baldini E, Resta ML, Bevilacqua G, Collecchi P. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum Pathol. 2009;40:1408-1417. [PMID: 19428048 DOI: 10.1016/j.humpath.2009.02.005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
647 Qiao C, Richter GT, Pan W, Jin Y, Lin X. Extracranial arteriovenous malformations: from bedside to bench. Mutagenesis 2019;34:299-306. [PMID: 31613971 DOI: 10.1093/mutage/gez028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
648 Osei E, Walters P, Masella O, Tennant Q, Fishwick A, Dadzie E, Bhangu A, Darko J. A review of predictive, prognostic and diagnostic biomarkers for brain tumours: towards personalised and targeted cancer therapy. J Radiother Pract 2021;20:83-98. [DOI: 10.1017/s1460396919000955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
649 Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012;181:401-12. [PMID: 22705054 DOI: 10.1016/j.ajpath.2012.04.026] [Cited by in Crossref: 233] [Cited by in F6Publishing: 222] [Article Influence: 23.3] [Reference Citation Analysis]
650 Hoekstra AV, Ward EC, Hardt JL, Lurain JR, Singh DK, Buttin BM, Schink JC, Kim JJ. Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gynecol Oncol 2008;108:609-18. [PMID: 18234299 DOI: 10.1016/j.ygyno.2007.11.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
651 Gautam A, Li ZR, Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene. 2003;22:2135-2142. [PMID: 12687015 DOI: 10.1038/sj.onc.1206232] [Cited by in Crossref: 101] [Cited by in F6Publishing: 98] [Article Influence: 5.3] [Reference Citation Analysis]
652 Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, Mizuno K, Hasegawa G, Kishimoto H, Iizuka M. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest. 2004;113:1774-1783. [PMID: 15199412 DOI: 10.1172/jci200420513] [Cited by in Crossref: 51] [Cited by in F6Publishing: 1] [Article Influence: 2.8] [Reference Citation Analysis]
653 Fu X, Wen H, Jing L, Yang Y, Wang W, Liang X, Nan K, Yao Y, Tian T. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Sci. 2017;108:620-631. [PMID: 28132399 DOI: 10.1111/cas.13177] [Cited by in Crossref: 64] [Cited by in F6Publishing: 81] [Article Influence: 12.8] [Reference Citation Analysis]
654 Kim JS, Xu X, Li H, Solomon D, Lane WS, Jin T, Waldman T. Mechanistic analysis of a DNA damage-induced, PTEN-dependent size checkpoint in human cells. Mol Cell Biol. 2011;31:2756-2771. [PMID: 21536651 DOI: 10.1128/mcb.01323-10] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
655 Pilarsky CP, Schmidt U, Eißrich C, Stade J, Froschermaier SE, Haase M, Faller G, Kirchner TW, Wirth MP. Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 1998;36:85-91. [DOI: 10.1002/(sici)1097-0045(19980701)36:2<85::aid-pros3>3.0.co;2-d] [Cited by in Crossref: 64] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
656 Rogers HA, Estranero J, Gudka K, Grundy RG. The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors. Oncotarget 2017;8:2083-95. [PMID: 27926496 DOI: 10.18632/oncotarget.13781] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
657 Álvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. Mechanisms of PTEN loss in cancer: It's all about diversity. Semin Cancer Biol 2019;59:66-79. [PMID: 30738865 DOI: 10.1016/j.semcancer.2019.02.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 17.7] [Reference Citation Analysis]
658 Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomäki P, de la Chapelle A, Aaltonen LA, Eng C. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol. 2002;161:439-447. [PMID: 12163369 DOI: 10.1016/s0002-9440(10)64200-9] [Cited by in Crossref: 131] [Cited by in F6Publishing: 71] [Article Influence: 6.6] [Reference Citation Analysis]
659 Li L, Sun JX, Wang XQ, Liu XK, Chen XX, Zhang B, He ZD, Liu DZ, Chen LX, Wang LW, Huang Z. Notoginsenoside R7 suppresses cervical cancer via PI3K/PTEN/Akt/mTOR signaling. Oncotarget 2017;8:109487-96. [PMID: 29312623 DOI: 10.18632/oncotarget.22721] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
660 Clement E, Inuzuka H, Nihira NT, Wei W, Toker A. Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors. Sci Signal 2018;11:eaao3810. [PMID: 29535262 DOI: 10.1126/scisignal.aao3810] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
661 Liu B, Cheng Y, Liu Q, Bao JK, Yang JM. Autophagic pathways as new targets for cancer drug development. Acta Pharmacol Sin 2010;31:1154-64. [PMID: 20694022 DOI: 10.1038/aps.2010.118] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 6.4] [Reference Citation Analysis]
662 Shima N, Pederson KD. Dormant origins as a built-in safeguard in eukaryotic DNA replication against genome instability and disease development. DNA Repair (Amst) 2017;56:166-73. [PMID: 28641940 DOI: 10.1016/j.dnarep.2017.06.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
663 Pan L, Lu J, Wang X, Han L, Zhang Y, Han S, Huang B. Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer 2007;109:1676-88. [PMID: 17330857 DOI: 10.1002/cncr.22585] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
664 Dolcet X, Llobet D, Pallares J, Matias-guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005;446:475-82. [DOI: 10.1007/s00428-005-1264-9] [Cited by in Crossref: 571] [Cited by in F6Publishing: 556] [Article Influence: 33.6] [Reference Citation Analysis]
665 Rameh LE, Cantley LC. The Role of Phosphoinositide 3-Kinase Lipid Products in Cell Function. Journal of Biological Chemistry 1999;274:8347-50. [DOI: 10.1074/jbc.274.13.8347] [Cited by in Crossref: 720] [Cited by in F6Publishing: 679] [Article Influence: 31.3] [Reference Citation Analysis]
666 Zhong T, Zhou J, Zhan S, Wang L, Niu L, Guo J, Li L, Zhang H. Molecular Characteristics, Phylogeny and Expression Profile of the PTEN Gene in Goats. Biochem Genet 2020;58:399-411. [PMID: 32020391 DOI: 10.1007/s10528-020-09947-0] [Reference Citation Analysis]
667 Cotter K, Rubin MA. The evolving landscape of prostate cancer somatic mutations. Prostate 2022;82 Suppl 1:S13-24. [PMID: 35657155 DOI: 10.1002/pros.24353] [Reference Citation Analysis]
668 Steelman LS, Bertrand FE, Mccubrey JA. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opinion on Therapeutic Targets 2005;8:537-50. [DOI: 10.1517/14728222.8.6.537] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 4.4] [Reference Citation Analysis]
669 Choi SW, Lee Y, Shin K, Koo H, Kim D, Sa JK, Cho HJ, Shin HM, Lee SJ, Kim H, Chung S, Shin J, Lee C, Nam DH. Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma. Cell Death Dis 2021;12:374. [PMID: 33828082 DOI: 10.1038/s41419-021-03657-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
670 Huang X, Begley M, Morgenstern KA, Gu Y, Rose P, Zhao H, Zhu X. Crystal structure of an inactive Akt2 kinase domain. Structure 2003;11:21-30. [PMID: 12517337 DOI: 10.1016/s0969-2126(02)00937-1] [Cited by in Crossref: 92] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
671 Rumpel CA, Powell SM, Moskaluk CA. Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol 1999;154:1329-34. [PMID: 10329585 DOI: 10.1016/S0002-9440(10)65386-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
672 Abdel-Rahman MH, Yang Y, Zhou XP, Craig EL, Davidorf FH, Eng C. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J Clin Oncol 2006;24:288-95. [PMID: 16344319 DOI: 10.1200/JCO.2005.02.2418] [Cited by in Crossref: 79] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
673 Assis LV, Isoldi MC. Overview of the biochemical and genetic processes in malignant mesothelioma. J Bras Pneumol 2014;40:429-42. [PMID: 25210967 DOI: 10.1590/s1806-37132014000400012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
674 Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A 2005;102:18443-8. [PMID: 16339315 DOI: 10.1073/pnas.0508988102] [Cited by in Crossref: 247] [Cited by in F6Publishing: 241] [Article Influence: 14.5] [Reference Citation Analysis]
675 Ozsu E, Sen A, Ceylaner S. A case of Riley Ruvalcaba syndrome with a novel PTEN mutation accompanied by diffuse testicular microlithiasis and precocious puberty. Journal of Pediatric Endocrinology and Metabolism 2018;31:95-9. [DOI: 10.1515/jpem-2017-0250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
676 Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ, Ashworth A, Reis-Filho JS. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010;2:53ra75. [PMID: 20944090 DOI: 10.1126/scitranslmed.3001538] [Cited by in Crossref: 162] [Cited by in F6Publishing: 159] [Article Influence: 14.7] [Reference Citation Analysis]
677 Haynie DT, Xue B. Superdomains in the protein structure hierarchy: The case of PTP-C2. Protein Sci 2015;24:874-82. [PMID: 25694109 DOI: 10.1002/pro.2664] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
678 Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117-127. [PMID: 15324695 DOI: 10.1016/j.ccr.2004.06.022] [Cited by in Crossref: 1256] [Cited by in F6Publishing: 1106] [Article Influence: 69.8] [Reference Citation Analysis]
679 Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003;3:559-70. [PMID: 12894244 DOI: 10.1038/nrc1145] [Cited by in Crossref: 196] [Cited by in F6Publishing: 163] [Article Influence: 10.3] [Reference Citation Analysis]
680 Sobottka SB, Haase M, Fitze G, Hahn M, Schackert HK, Schackert G. Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain. J Neurooncol 2000;49:187-95. [PMID: 11212897 DOI: 10.1023/a:1006442024874] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
681 Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 2008;124:31-42. [DOI: 10.1007/s00439-008-0529-1] [Cited by in Crossref: 197] [Cited by in F6Publishing: 167] [Article Influence: 14.1] [Reference Citation Analysis]
682 Li J, Di C, Mattox AK, Wu L, Adamson DC. The future role of personalized medicine in the treatment of glioblastoma multiforme. Pharmgenomics Pers Med 2010;3:111-27. [PMID: 23226047 DOI: 10.2147/PGPM.S6852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
683 Csolle MP, Ooms LM, Papa A, Mitchell CA. PTEN and Other PtdIns(3,4,5)P3 Lipid Phosphatases in Breast Cancer. Int J Mol Sci 2020;21:E9189. [PMID: 33276499 DOI: 10.3390/ijms21239189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
684 Chen Y, Huang WC, Séjourné J, Clipperton-Allen AE, Page DT. Pten Mutations Alter Brain Growth Trajectory and Allocation of Cell Types through Elevated β-Catenin Signaling. J Neurosci 2015;35:10252-67. [PMID: 26180201 DOI: 10.1523/JNEUROSCI.5272-14.2015] [Cited by in Crossref: 66] [Cited by in F6Publishing: 42] [Article Influence: 9.4] [Reference Citation Analysis]
685 Nip H, Dar AA, Saini S, Colden M, Varahram S, Chowdhary H, Yamamura S, Mitsui Y, Tanaka Y, Kato T, Hashimoto Y, Shiina M, Kulkarni P, Dasgupta P, Imai-Sumida M, Tabatabai ZL, Greene K, Deng G, Dahiya R, Majid S. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget 2016;7:68371-84. [PMID: 27634912 DOI: 10.18632/oncotarget.12031] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]
686 Mckenna WG, Muschel RJ. Targeting tumor cells by enhancing radiation sensitivity.